JOSH GREEN, M.D. GOVERNOR KE KIA'ĀINA



STATE OF HAWAI'I | KA MOKU'ĀINA O HAWAI'I DEPARTMENT OF ACCOUNTING AND GENERAL SERVICES | KA 'OIHANA LOIHELU A LAWELAWE LAULĀ

OFFICE OF ENTERPRISE TECHNOLOGY SERVICES | KE'ENA HO'OLANA 'ENEHANA

P.O. BOX 119, HONOLULU, HAWAII 96810-0119

March 13, 2025

The Honorable Ronald D. Kouchi President of the Senate and Members of the Senate Thirty-Third State Legislature State Capitol, Room 409 Honolulu, Hawai'i 96813 The Honorable Nadine K. Nakamura Speaker and Members of the House of Representatives Thirty-Third State Legislature State Capitol, Room 431 Honolulu, Hawai'i 96813

Aloha Senate President Kouchi, Speaker Nakamura, and Members of the Legislature:

Pursuant to HRS section 27-43.6, which requires the Chief Information Officer to submit applicable independent verification and validation (IV&V) reports to the Legislature within ten days of receiving the report, please find attached the report the Office of Enterprise Technology Services received for the State of Hawai'i, Department of Health, BHA Integrated Case Management System Project.

In accordance with HRS section 93-16, this report may be viewed electronically at <u>http://ets.hawaii.gov</u> (see "Reports").

Sincerely,

Christine M. Sakuda Chief Information Officer State of Hawai'i

Attachments (2)



Hawaii BHA Integrated Case Management System Project – Phase 4

IV&V Report for the period of February 1 – February 28, 2025

Final Submitted: March 12, 2025



Solutions that Matter

Agenda

Executive Summary IV&V Findings & Recommendations

Appendices

- A Rating Scales
- B Inputs
- C Project Trends
- D Acronyms and Definitions
- E List of Production Defects





The project continues to show progress in the buildout of additional system features. The new Adverse Event Reporting functionality went live this month, receiving positive feedback from users regarding its usability and the training provided by the Systems Integrator (SI).

The project is making progress toward addressing the previously reported regression testing challenges and is preparing to bring on board an automated regression testing tool (Tosca) expert.

Manual regression testing will continue until automated tests can be repaired, potentially impacting testing productivity and comprehensiveness. The project continues to work to address production defects. The SI has committed to enhancing Smoke Test scripts to include more comprehensive testing, such as for the Provider Portal.

The addition of the Tosca SME should also help to address the previously reported BHA resource constraints. BHA is also making efforts to capture existing project team member knowledge to ensure their system, operational, and technical knowledge is not lost when members leave. They plan to utilize their existing system platform (Dynamics CRM) to establish a centralized knowledge base for capturing projects and other relevant knowledge.

The previously reported ambiguity regarding contractual terms and conditions related to defect charges has been resolved and clarified. Defects will only incur charges if they are not identified during joint testing. IV&V continues to recommend strengthened testing measures to ensure defects are identified during joint testing.

IV&V closed three findings: The first pertains to sprint reviews, the second to unreported AERs, and the third to cost tracking for big rocks. Finding 34 related to sprint reviews and system demonstrations was closed, as BHA is satisfied with their current approach of conducting ad-hoc demos rather than regimented end-of-sprint demos and has acknowledged and accepted this risk. Additionally, IV&V closed finding 49 regarding multiple AERs for a single episode and false positives, as the project confirmed that claims are currently being attributed to unreported AERs. Lastly, finding 45 related to cost tracking, federal financial participation allotments, and claims management were closed, as the project does not have control over the Med-QUEST Division (MQD) processes.



Dec	Jan	Feb	Category	V&V Observations	
				IV&V has closed the finding related to sprint reviews and system demonstrations as BHA is satisfied with their current approach of conducting ad-hoc demos rather than regimented end-of-sprint demos. They have acknowledged and accepted this risk.	
Y Y Sprint Planning		Sprint Planning	BHA plans to schedule other backlog review meetings and will notify IV&V accordingly. While some meetings have already occurred, a consistent backlog review schedule is still being established. Efforts are also underway to improve the backlog review process. Regular meetings and process enhancements will help ensure alignment, facilitate timely issue resolution, and keep the project moving forward efficiently.		
G	0	G	User Story (US) Validation	There are no active findings in the User Story (US) Validation category, which remains Green (low criticality) for this reporting period. IV&V will continue to monitor the US development and validation process in upcoming reporting periods.	
Y			The project is making progress toward addressing the previously reported regression testing challenges and is preparing to bring on board an automated regression testing tool (Tosca) expert.		



Dec	Jan	Feb	Category	IV&V Observations
Y	Y	Y	Release / Deployment Planning	The R4.9 deployment defect remains unresolved. R4.10 was deployed on 2/6/2025, with a critical defect reported the same day, leading to a hotfix on 2/7/2025. Since then, five additional production defects have been logged, with Root Cause Analysis (RCA) still pending. The AER solution went live on 2/21/2025 alongside a Mid-Sprint Deployment (MSD) with two new items. The R4.11 go-live is scheduled for 4/3/2025. IV&V will continue monitoring the deployment quality of R4.10, Fast Healthcare Interoperability Resources (FHIR), any MSDs, and the AER solution.

5

Dec	Jan	Feb	Category	IV&V Observations	
0	G	G	On-The-Job- Training (OJT) and Knowledge Transfer (KT) Sessions	ning (OJT) Knowledge nsfer (KT) This category remains Green (low criticality) for the February reporting period with no active findings.	
G	G	G	Targeted KT	This category remains Green (low criticality) for the February reporting period IV&V will	
G	G	G	Project Performance Metrics	There are no project performance metrics to report for the February reporting period. IV&V will keep this category's criticality rating Green (low criticality) and will continue to monitor.	
G	G	G	Organizational Maturity Assessment (OMA)	This category remains Green (low criticality) for the February reporting period. There are no outstanding findings in this category, and IV&V will continue to monitor.	



Dec	Jan	Feb	Category	IV&V Observations
Y	Y	Y	Project Management	The new Adverse Event Reporting functionality went live this month, receiving positive feedback from users regarding its usability and the training provided by the SI. The previously reported ambiguity regarding contractual terms and conditions related to defect charges has been resolved and clarified. Defects will only incur charges if they are not identified during joint testing. IV&V continues to recommend strengthened testing measures to ensure defects are identified during joint testing.

Dec	Jan	Feb	Category	IV&V Observations
Y	Y	Y	Resource Management	The addition of the Tosca SME should also help to address the previously reported BHA resource constraints. BHA is also making efforts to capture existing project team member knowledge to ensure their system, operational, and technical knowledge is not lost when members leave. They plan to utilize their existing system platform (Dynamics CRM) to establish a centralized knowledge base for capturing projects and other relevant knowledge.



As of the February 2025 reporting period, Eleven (11) open findings were updated – Seven (7) Medium Issues, one (1) Medium Risks, three (3) Low Issue spread across the Release/Deployment Planning, Test Practice Validation, Sprint Planning, Project Management, Resource Management, assessment areas are currently open.



Open Risks/Issues by Category/Preliminary





Assessment Categories

Throughout this project, IV&V verifies and validates activities performed in the following process areas:

- Sprint Planning
- User Story Validation
- Test Practice Validation
- Release / Deployment Planning
- On-the-Job Training (OJT) and Knowledge Transition (KT) Sessions
- Targeted Knowledge Transition (KT)
- Project Performance Metrics
- Organizational Maturity Assessment
- Project Management
- Resource Management



Sprint Planning

#	Key Findings	Criticality Rating
31	 Medium Risk: A lack of regular Sprint Reviews and Sprint Demos will likely lead to misalignments between delivered work and stakeholder needs. Finding Update: CAMHD conducted a demo for stakeholders, receiving valuable feedback confirming the design aligned with business needs. It has been agreed that demos will be conducted on a case-by-case basis moving forward. DDD has actively involved key team members in joint testing sessions, which has ensured a more comprehensive review and provided diverse insights. This involvement helps identify potential issues early and enhances overall testing effectiveness. Additionally, DDD is assessing whether a sprint demo is necessary for the calculator functionality, but their current process is proving effective in meeting business requirements. As a result, IV&V has closed the risk. 	Closed

Recommendations	Status
According to Agile Best Practices, IV&V recommends including Sprint Reviews and Demos in future releases (R4.2 and onwards). At the end of each sprint, conduct a sprint review meeting to demonstrate the completed work to stakeholders and gather feedback. Use this feedback to refine and reprioritize the product backlog. For a two-month sprint, IV&V recommends having more than one (1) demo during the sprint.	In Progress
Create a stakeholder register to identify all stakeholders. List their identification, assessment, and classification. Review the register regularly to plan appropriate stakeholder engagement.	In Progress
Foster active participation from users and stakeholders during both Sprint Reviews and Sprint Demos. Emphasize the value of iterative feedback to guide development and ensure that user needs are consistently met.	In Progress



IV&V Findings & Recommendations Sprint Planning (cont'd)

Recommendations	Status
Establish standardized communication protocols for both Sprint Reviews and Sprint Demos. Encourage teams to deliver concise and informative progress reports, including achievements, challenges, and plans. This will enhance stakeholder engagement and project transparency.	In Progress
Institute a structured documentation process for Sprint Reviews and Sprint Demos. Document key decisions, action items, and insights from each session to ensure accountability and to support ongoing process improvement.	In Progress



IV&V Findings & Recommendations Sprint Planning (cont'd)

#	Key Findings	Criticality Rating
41	 Medium Risk: The absence of separate dedicated product backlog review meetings can lead to unclear priorities, misalignment with stakeholders, inadequate refinement, and an increased risk of scope creep. Finding Update: BHA plans to schedule other backlog review meetings and will notify IV&V accordingly. While some meetings have already taken place, a consistent backlog review schedule is still being established. Efforts are also underway to improve the backlog review process. Regular meetings, along with process enhancements, will help ensure alignment, facilitate timely issue resolution, and keep the project moving forward efficiently. 	M

Recommendations	Status
CAMHD and DDD implement a structured feedback management process with a prioritization framework to ensure that all new requests are thoroughly evaluated and aligned with project goals before being added to the backlog.	Open
Separate dedicated product backlog review meetings (during Sprints) would allow clarifying any ambiguities or uncertainties, re-prioritization, estimation and refinement of backlog items. This would allow the project team to avoid situations where decisions about including items mid-Sprint would have to be taken.	Open
IV&V recommends scheduling separate dedicated product backlog review meetings (during Sprints) where all relevant stakeholders are invited to review the product backlog and scheduled at the appropriate time(s) such that there is sufficient time to plan the design, development, and implementation (DDI) of the next release(s).	Open



Test Practice Validation

#	Key Findings	Criticality Rating
2	 Medium Issue: As a result of regression testing not being consistently performed, production releases are breaking existing functionality in the production environment. Finding Update: Regression Testing for R4.11 is scheduled from 3/25/2025 to 4/2/2025. CAMHD will perform both manual and automated tests, while DDD will focus exclusively on manual regression testing. To support future Phase 4 releases, including R4.11 and beyond, the project will onboard a Tosca Automated Regression Testing SME, with the work set to begin on 3/10/2025. The SI has uploaded and executed one regression test case for the AER project and is preparing additional regression test scripts with estimated completion before the R4.11 go-live. 	M

Recommendations	Status
To ensure effective Tosca testing, it is crucial for both divisions to align on a unified resource allocation strategy. Given the limited availability of resources, open communication and consensus-building are essential for optimizing tester utilization. By collaborating to prioritize testing efforts, share critical test cases, and identify overlapping areas, the divisions can achieve comprehensive regression testing without overburdening a single resource. This collaborative approach will balance workloads, streamline processes, and enhance test coverage, minimizing delays and bottlenecks. Ultimately, it will enable both divisions to efficiently meet their testing objectives.	Open
A balanced approach that combines manual and automated regression testing to ensure broad test coverage and flexibility.	Open



IV&V Findings & Recommendations Test Practice Validation (cont'd)

Recommendations	Status
Having board(s) in Azure DevOps or a document on SharePoint that provides information about the status of regression testing automation, to facilitate visibility and transparency to BHA project personnel and stakeholders.	In Progress
Schedule priorities should be reevaluated by distributing the work according to the resource bandwidth. This will ensure that the schedule is not impacted and that the work is done efficiently between regression testing and Golden Record (GR) tasks.	In Progress
Pursue and complete additional formal training in Azure DevOps and Tricentis for test automation as soon as possible and complete efforts to automate the two primary regression test scripts.	In Progress
Determine if current regression testing timeframes are adequate, and if not, add more time to the pre-production regression test efforts for all release deployments.	In Progress



IV&V Findings & Recommendations Test Practice Validation (cont'd)

#	Key Findings	Criticality Rating
40	 Medium Issue: Insufficient testing processes can lead to poor-quality software, project delays, and extended user acceptance testing. Finding Update: R4.10 was deployed to production on 2/6/2025. Since the deployment of R4.10, five additional unresolved production defects have been recorded in Azure DevOps (ADO) (see Appendix E for details): two high severity, two medium severity, and one low severity—despite testing at the unit, SIT, regression, joint, and smoke testing levels. In response, the SI has committed to enhancing Smoke Test scripts to include more comprehensive testing, such as for the Provider Portal. The project plans to onboard an Automated Regression Testing Tool (Tosca) expert, with work planned to begin sometime in the month of March 2025. The project hopes to utilize this expert to repair existing Tosca scripts so they can restart automated testing efforts. User Acceptance Testing for AER functionality was completed successfully with BHA approving the AER testing deliverables. The AER solution went live on 2/21/2025. 	M
Recor	nmendations	Status

IV&V has requested an overview of the testing process, with a focus on process such as tracking test coverage In Progress and requirements traceability.

IV&V Findings & Recommendations Test Practice Validation (cont'd)

Recommendations	Status
IV&V has requested an overview of the testing process, with a focus on process such as tracking test coverage and requirements traceability.	In Progress
A Stakeholder Register helps identify and understand all project stakeholders, ensuring needs are met and risks are managed through effective communication. A RACI matrix clarifies roles and responsibilities, improving collaboration, decision-making, and resource management, which are all critical for the success of IT projects.	In Progress
Identify stakeholders (output is Stakeholder Register) and develop a RACI matrix for testing.	In Progress
Review the overall testing process and implement any needed improvements identified.	Open



IV&V Findings & Recommendations Release / Deployment Planning (cont'd)

#	Key Findings	Criticality Rating
39	 Low Issue: Due to on-going deployment processes and technical execution issues, the Project may continue to encounter defects and challenges, e.g., when releases are in production or in meeting projected timelines for production and non-production deployments. Finding Update: The R4.9 deployment-related defect is yet to be addressed. R4.10 was deployed to production on 2/6/2025. That same day, users reported a critical defect, prompting the deployment of a hotfix with a workaround on 2/7/2025. Since the R4.10 deployment, five additional unresolved production defects have been logged in Azure DevOps (ADO): two high severity, two medium severity, and one low severity. Their Root Cause Analysis (RCA) is still pending. Additionally, the AER solution went live on 2/21/2025, and a Mid-Sprint Deployment (MSD) with two (2) new items were deployed the same day. The R4.11 go-live is scheduled for 4/3/2025. IV&V will continue to monitor the deployment quality of R4.10, FHIR, any MSDs, and the AER solution. 	

Recommendations	Status
The project should consider automating deployments for resource savings, increased efficiency, consistency, faster time to market, improved collaboration and reliability, scalability, version control integration, and rollback capability.	Open
Ensure there are adequate and qualified resources to support the current deployment processes. This may require support from RSM resources to provide assistance and knowledge transfer for some more complex deployment components.	Open



IV&V Findings & Recommendations Release / Deployment Planning (cont'd)

Recommendations	Status
As appropriate, consult with RSM on best practices that BHA could employ to support deployment.	Open
Request the assistance of the RSM Solution Architect in reviewing and correcting issues associated with the consistency of configurations across environments, ensuring that the test environment is capable of testing ALL functions of any given release without the need for using multiple test environments.	Open
Request assistance from the RSM Solution Architect in reviewing deployment scripts to double-check for accuracy and completeness before commencing deployment activities.	Open
The Project Team should consider evaluating potential changes to improve/enhance existing processes and communications to address current release/deployment shortfalls.	Open
IV&V recommends performing a Root Cause Analysis (RCA) in collaboration with RSM for the continued concerns surrounding environment differences.	Open
IV&V recommends updating the Project's Configuration Management Plan to address the current needs of the Project. This should include specific checklists geared at ensuring repeatable promotional processes by DOH.	Open
Look at implementing 'hard' code freeze dates as well as test environment deployment dates to ensure that testing and deployment activities are not rushed.	Open
Ensure an operational and fully functional test environment is available to effectively conduct end-to-end regression testing prior to deploying a release to production.	Open
Develop a plan to institutionalize the execution of smoke testing for promotions to non-production and production environments. This will help to ensure that all components needed to test have been properly deployed prior to the actual execution of test activities.	Open

Release / Deployment Planning

#	Key Findings	Criticality Rating
43	Low Issue: Execution time for the process for updating DDD SharePoint folders was unacceptable. Finding Update: Further development on planned improvements to an existing process is linked to the scanning project. The SI has provided project cost and timeline information for the restart of this project and is ready to commence the project. DDD has not yet received the Governor's approval. Once approved, the scanning project will commence. IV&V has reduced the risk rating to low.	

Recommendations	Status
IV&V recommends doing an impact analysis, e.g., downstream impact.	Open
IV&V recommends that DDD puts on hold any development utilizing Power Automate for the performance issue encountered in production (marked "TBD" in finding #14 related to "SharePoint Bulk Flows still running") and related User Stores, e.g., "Changes to DDD folders," and defects.	Open
IV&V recommends evaluating other feasible options, e.g., leveraging SharePoint tools and best practices.	Open
A project issue should be opened to identify and manage the resolution of this issue.	Open



Project Management (cont'd)

#	Key Findings	Criticality Rating
14	 Medium Issue: Due to multiple quality concerns, the project may continue to face impactful system defects. Finding Update: R4.10 was deployed to production on 2/6/2025. That same day, users reported a critical defect, prompting the deployment of a hotfix with a workaround on 2/7/2025. Following the deployment of R4.10, the project has recorded five additional unresolved production defects: two high severity, two medium severity, and one low severity, in Azure DevOps (ADO)—(see Appendix E for details). BHA is prioritizing higher-priority tasks, which has delayed addressing these lower-priority defects, though remediation efforts are underway. Additionally, the AER solution went live on 2/21/2025, and a Mid-Sprint Deployment (MSD) with two (2) new items deployed the same day. The R4.11 go-live is scheduled for 4/3/2025. IV&V remains concerned about code quality and will continue to monitor R4.10, FHIR, any MSDs, and the AER solution. 	M

Recommendations	Status
The project have discussions around utilizing tools such as SonarQube for continuous inspection of code quality and establishing a source code quality threshold to maintain high-quality, secure, and maintainable code.	Open
The project increases comprehensive testing prior to joint testing to reduce the burden on BHA testers and reduce post-production defects.	Open
The SI vendor add a "Found In" column to the daily scrum file to indicate the environment where each defect was identified.	In Progress
The SI vendor provides the total number of defects in production and reports these numbers regularly to BHA.	In Progress



Recommendations	Status
Evaluate existing project staff skills and experience levels to ensure they meet BHA support requirements.	In Progress
Perform CAMHD revenue neutrality fiscal balance testing on a quarterly basis to ensure revenues are as expected.	In Progress



#	Key Findings	Criticality Rating
	Low Issue: Performance bottlenecks with the INSPIRE production environment may result in low productivity and poor user experience.	•
33	Finding Update: Production system performance remains stable with no current issues; however, DDD has reported that test environments have significantly slowed down, a concern particularly evident during AER training. IV&V has reduced the risk rating to low.	

Recommendations	Status
IV&V recommends: BHA execute a performance test during the development of R4.6 (planned completion 5/20/2024), identifying test cases and scenarios that include both DDD and CAMHD functionality, transactions/functionality that are performance intensive, e.g., calculator functionality	In Progress
Conduct load and performance testing for each release that has significant new features/functionality, e.g., Calculator-related transactions.	Open
Create a plan for comprehensive performance testing and address any performance bottlenecks.	Open
Have the benchmark assessments done annually and implementation of Azure App Insights for Power Platform.	Open
Execute test scripts that measure the run-time for execution of long-running transactions. E.g., Calculator functionality/transactions and monitoring results over time.	Open



#	Key Findings	Criticality Rating
42	Medium Issue: Lack of effective governance and communication among stakeholders can have significant negative impacts on a project in several ways.	M
	Finding update: DDD clarified that, except in cases of a missed requirement, any defect found during testing incurs 0 USPs; otherwise, BHA is responsible for the cost of fixing the defect.	

Recommendations	Status
Establish a mutual understanding of the contractual terms and conditions: BHA and the SI have discussions to align on a shared understanding of the contractual terms and conditions for the INSPIRE project.	Closed
Create a Governance Structure: Implement a governance structure that defines decision-making processes, escalation procedures, and accountability mechanisms. Clarify how decisions will be made, who has authority, and how issues will be resolved.	Open
Develop a Stakeholder Registry, RACI Matrix, and Stakeholder Engagement Plan: Identify key stakeholders and develop a plan to engage them throughout the project lifecycle. Tailor communication strategies to address the needs and preferences of different stakeholders, ensuring their active involvement and support.	Open
Clearly Define Roles and Responsibilities: Clearly outlining the roles and responsibilities of each stakeholder involved in the project, would ensure that everyone understands their duties and how they contribute to the project's success.	Open



Recommendations	Status
Encourage Open Communication and Feedback: Foster a culture of open communication and feedback where stakeholders feel comfortable sharing their thoughts, concerns, and suggestions. Encourage constructive dialogue and actively seek input to improve decision-making and problem-solving. Keep stakeholders informed about project progress, milestones, and key developments through regular updates and progress reports. Highlight achievements, challenges, and any changes to the project plan or scope.	Open
Resolve Conflicts Promptly: Address conflicts and disagreements among stakeholders promptly and professionally. Encourage dialogue, active listening, and compromise to find mutually acceptable solutions that support project goals.	Open
Manage Expectations: Manage stakeholders' expectations by setting realistic timelines, budgets, and deliverables. Foster a culture of transparency about project constraints and risks and proactively communicate any changes or deviations from the plan.	Open
Evaluate and Adapt: Continuously evaluate the effectiveness of governance and communication processes and adjust as needed. Solicit stakeholders' feedback to identify areas for improvement and continuously refine your approach.	Open



#	Key Findings	Criticality Rating
45	Medium Issue: There is a lack of stakeholder alignment on cost tracking, federal financial participation allotments, and claims management. Finding update: There has been no progress for this reporting period.	Closed

Recommendations	Status
IV&V recommends that stakeholders establish a structured process to ensure alignment and guide resolution.	Open



#	Key Findings	Criticality Rating
46	 Medium Issue: Neglecting the established defect management process could lead to lost/forgotten defects and user frustration and could slow the resolution of similar defects in the future. Finding Update: A high-priority defect occurred on 2/6/2025, bringing to light an opportunity to strengthen the project's defect management process. BHA encountered some challenges that resulted in a delay in addressing the defect. In February, there were productive discussions on addressing critical defects. The SI has provided a document outlining the Help Desk process, which IV&V will review in March 2025 to further determine the risk. 	M

Recommendations	Status
 IV&V recommends to: 1. Send communications to the project stakeholders to clarify the defect management process and the importance of logging all defects. 2. Take steps to assure current and new users understand how to report and/or log defects. 3. Consider designating a defect management lead or champion to oversee adherence to the process and assure all defects are logged. 4. Keep stakeholders informed about defect status, priority, impacts, and resolution timelines. This could increase awareness of the importance of logging defects. 5. Discuss ways to improve the defect logging and management process with the SI and come up with a plan to improve. 	Open



#	Key Findings	Criticality Rating
47	Medium Issue: The lack of a governance process for restarting production systems can impact service availability and frustrate end-users and hinder accountability.Finding Update: There has been no progress for this reporting period.	M

Recommendations	Status
 IV&V recommends BHA 1. Develop standard procedures for system restarts, including pre-checks, step-by-step instructions, and post-restart verifications. 2. Require formal approvals before initiating a restart, especially for INSPIRE, and document all actions in a centralized system. 3. Define clear escalation paths for when restarts do not go as planned, including identifying contacts for technical support and management approval for additional interventions. 4. Automate Restart Procedures where possible. 5. The governance process is established, it should be effectively communicated to the project team. 6. Provide stakeholders with a clear explanation of the reason for the restart and the lessons learned, while documenting the restart details in the defect record. 	Open



#	Key Findings	Criticality Rating
49	Medium Issue: Multiple AERs for a single episode and false positives.	
	New Finding: DDD informed IV&V that the SI's AER team has successfully designed and demonstrated functional, visually appealing dashboards. Phase 1 of the AER solution, focused on Case Management, has completed UAT and went live on 2/21/2025. A Mid-Sprint Deployment (MSD) on the same day introduced two new items: unreported AERs and false positives.	Closed
	Additionally, new requests—such as enhanced reporting for the Outcomes & Compliance Branch (OCB), Clinical Integration Team (CIT), and Community Resources Branch (CRB) on trending insights—are being designed and will be deployed in Phase 2.	



IV&V Findings & Recommendations Schedule Management

#	Key Findings	Criticality Rating
	Preliminary Concern: There is uncertainty around the scheduling, trainee groupings, and access to training materials for upcoming training sessions.	
50	New Finding: IV&V was informed that the RSM team members had demonstrated strong troubleshooting skills. During the UAT phase, they were able to quickly diagnose issues, showcasing their efficiency in problem-solving. In the third supervisor training session, one of the trainees had trouble viewing the screen. The RSM team member addressed the issue by providing the trainee with the relevant page numbers from the training manual, ensuring they could follow along without any disruption.	Closed
	As the issue was resolved, we are now closing this preliminary concern.	



IV&V Findings & Recommendations Resource Management

#	Key Findings	Criticality Rating			
	Medium Issue: A shortage of BHA project resources could lead to reduced productivity and project delays.				
34	Finding Update: BHA is developing a succession plan to address the potential departure of key personnel and is actively working on having resources document knowledge as team members transition. This proactive approach aims to ensure continuity and preserve essential information. One example of this effort is creating a knowledge base within the Help Desk system in Dynamics, which serves as a centralized resource for troubleshooting and support processes. By documenting processes, workflows, and troubleshooting steps, BHA ensures that future staff can access the same information and continue operations smoothly, even as experienced team members move on.	M			
Rec	ommendations	Ratingas could lead to reduced productivity and projectlan to address the potential departure of key es document knowledge as team members pontinuity and preserve essential information. One within the Help Desk system in Dynamics, which 			
expe	zing peer-to-peer knowledge sharing, allowing experienced team members to informally share their ertise during team meetings. Additionally, creating internal documentation that outlines best practices and esses for developing security policies would serve as a self-service resource for the team.	Open			
DDD and CAMHD have further discussions to optimize resource utilization between the two divisions.					
BHA	should explore options for offloading project team members' daily responsibilities to other staff.	In Progress			
BHA	should work quickly to create new positions and receive State approval.	In Progress			
BHA should identify tasks and duties that they can ask the SI to assume, as permitted by the contract, which are presently being handled by BHA members.					
BHA should explore the use of contractors to fulfill the functions for open project positions.					

IV&V Findings & Recommendations Project Performance Metrics

Metric	Description	IV&V Observations		IV&V	Updates	
	 Review and validate the velocity data as reported by the 	the velocity data as reported by the projectFebruary: R4.10 was deployed to production on 2/6/2024. AER was deployed to production on 2/21/2024 and a mid-sprint deployment with AER	Velocity Metric Trends:			
Velocity	project		Release	Planned velocity	Actual velocity	Percentage attained
	on pace to hit the total target number of US/USP	items followed on the same day.	R4.10	111	162	146

Release	Planned velocity	Actual velocity	Cumulative variance
R4.1	309	114	-195
R4.2	85	174	-106
R4.3	85	124	-67
Golden Record Mid-Sprint (MSD)	0	68	1
R4.4	240	225	-14
R4.5	95	76	-33
R4.6	84	103	-14
R4.7	111	50	-75
R4.8	111	107	-79
R4.9	111	71	-119
R4.10	111	162	-68

Phase 4 Releases Cumulative Variance



IV&V Findings & Recommendations Project Performance Metrics (cont'd.)

Metric	Description	IV&V Observations	IV&V Updates
Defect Metrics	 Understand and track the following: Defects by category (bug fixes) USPs assigned to defects in a release vs. USPs assigned to planned US in a release 	 February - Velocity was estimated at 111 USPs for R4.10, 162 R4.10 USPs were promoted to production on 2/6/25 and 2/212025. 9 of the 162 USPs were for defect fixing. •94% of the USPs were associated with user stories and requests. •6%* of the total USPs were associated with defects encountered during the release effort or pulled from the defect backlog. 	The defect percentage for December was 6%* which is under the target range of 20% or less of all USPs promoted to production.

Note*: This defect percentage does not include defects under warranty that are assigned zero (0) User Story Points.



Appendix A: IV&V Rating Scales
Appendix A IV&V Rating Scales

This appendix provides the details of each finding and recommendation identified by IV&V. Project stakeholders are encouraged to review the findings and recommendations log details as needed.

- See Findings and Recommendations Log (provided under separate cover)
- IV&V Assessment Category Rating Definitions

The assessment category is under control and the current scope can be delivered within the current schedule. The assessment category's risks and issues have been identified, and mitigation activities are effective. The overall impact of risk and issues is minimal. The assessment category is proceeding according to plan (< 30 days late). The assessment category is under control but also actively addressing resource, schedule or scope challenges that have arisen. There is a clear plan to get back on track. The assessment category's risk and/or issues have been identified, and further mitigation is required to facilitate forward (\mathbf{Y}) progress. The known impact of potential risks and known issues are likely to jeopardize the assessment category. Schedule issues are emerging (> 30 days but < 60 days late). Project leadership attention is required to ensure the assessment category is under control. The assessment category is not under control as there are serious problems with resources, schedule, or scope. A plan to get back on track is needed. The assessment category's risks and issues pose significant challenges and require immediate mitigation and/or escalation. The project's ability to complete critical tasks and/or meet the project's objectives is compromised and is R preventing the project from progressing forward. Significant schedule issues exist (> 60 days late). Milestone and task completion dates will need to be re-planned.

Executive management and/or project sponsorship attention is required to bring the assessment category under control.



Appendix A

Finding Criticality Ratings

Criticality Rating	Definition
•	A high rating is assigned if there is a possibility of substantial impact to product quality, scope, cost, or schedule. A major disruption is likely, and the consequences would be unacceptable. A different approach is required. Mitigation strategies should be evaluated and acted upon immediately.
M	A medium rating is assigned if there is a possibility of moderate impact to product quality, scope, cost, or schedule. Some disruption is likely, and a different approach may be required. Mitigation strategies should be implemented as soon as feasible.
	A low rating is assigned if there is a possibility of slight impact to product quality, scope, cost, or schedule. Minimal disruption is likely, and some oversight is most likely needed to ensure that the risk remains low. Mitigation strategies should be considered for implementation when possible.



Appendix B: Inputs



Appendix B Inputs

This appendix identifies the artifacts and activities that serve as the basis for the IV&V observations.

Meetings attended during the February 2025 reporting period:

- 1. Daily Scrum Meetings
- 2. Daily Design Meetings
- 3. Twice Weekly RSM Issues Meeting
- 4. Weekly BHA-ITS Program Status Meeting
- 5. Bi-Weekly Check-in: CAMHD
- 6. Bi-Weekly Check-in: DDD
- 7. BHA (CAMHD & DDD) IV&V Joint Meeting
- 8. IV&V Draft IV&V Status Review Meeting with DOH
- 9. DOH BHA IT Solution Project Steering Committee
- 10. US# Testing & Request Items
- 11. AER Analytics Bi-weekly Meeting
- 12. IV&V Interviews
- 13. INSPIRE Strategy Meeting

Eclipse IV&V[®] Base Standards and Checklists



Artifacts reviewed during the February 2025 reporting period:

- 1. Daily Scrum Notes
- 2. Twice Weekly Issues Meeting Notes
- 3. Weekly BHA-ITS Program Status Report
- 4. Release 4.7 Release Notes



Appendix C: Project Trends

Appendix C Project Trends

	May	June	July	August	September	October	November	December	January	February
User Story Validation										
Test Practice Validation										
Sprint Planning										
Release / Deployment Planning										
OJT and KT Sessions										
Targeted KT										
Project Performance Metrics										
Organization al Maturity Metrics										
General Project Management										
Resource Management										
7.1.0										
Total Open Findings	13	13	12	12	14	14	14	14	14	11
Issue - high	0	0	0	0	0	0	0	0	0	0
Issue - medium	8	8	8	8	10	10	10	10	10	7
Issue - low	1	1	1	1	1	1	1	1	1	3
Risk - high	0	0	0	0	0	0	0	0	0	0
Risk - medium	2	2	2	2	2	2	2	2	2	1
Risk - low	0	0	0	0	0	0	0	0	0	0
Preliminary Concern	2	2	1	1	2	2	2	2	2	0



Appendix D Acronyms and Definitions

Acronyms	Definition
DOH	Department of Health
BHA	Behavioral Health Services Administration
CAMHD	Child & Adolescent Mental Health Division
FHIR	Fast Healthcare Interoperability Resources
DDI	Design Development Implementation
DDD	Developmental Disabilities Division
SI	System Integrator
USP	User Story Points
SME	Subject Matter Expert
SIT	System Integration Testing
MS	Microsoft
MSD	Mid Sprint Deployment
ADO	Azure DevOps
SLA	Service Level Agreement
RCA	Root Cause Analysis
UAT	User acceptance testing
OJT	On-the-Job Training
KT	Knowledge Transition
SFTP	Secure File Transfer Protocol
IV&V	Independent Verification and Validation
MQD	Med-QUEST Division
CMS	Centers for Medicare & Medicaid Services
AER	Adverse Events Report

42

Appendix E List of Production Defects

ID 👻 V	Work Item Ty 👻	Divisi 👻	Title	✓ Prior ✓ Severity ✓ Found ✓	Created Date
33841 E	Bug	DDD	Bug - Calculator 3.0 - Users able to schedule service past ISP end date again	3 3 - Medium PROD	5/17/2023 8:22
34110 E	Bug	DDD	Bug - Individual Budget unlinking from Service Authorizations	2 3 - Medium PROD	7/27/2023 15:40
34238 E	Bug	CAMHD	BUG - Assessment Entity Initial Save Time - IMHE	2 3 - Medium Prod	8/17/2023 2:33
34242 E	Bug	DDD	Bug - Case Merge - Contact Notes not merging; Permissions error	2 3 - Medium PROD	8/17/2023 8:44
30634 E	Bug	CAMHD	CAMHD Bug - Credentialing documents not copied into PROD during Data Migration	3 3 - Medium PROD	2/16/2021 15:45
30726 E	3ug	DDD	Portal signature fields do not accept touchscreen input	2 3 - Medium PROD	9/17/2021 9:07
34969 E	3ug	DDD	Bug - Duplicate Provider Plans	1 3 - Medium PROD	2/23/2024 5:58
35041 E	Bug	DDD	Bug - Provider Portal AER Date/Time field for Treated by Ambulance/Emergency Medical Person is hidden on viewing in Edit Mode	2 3 - Medium Prod	3/11/2024 8:47
33550 E	Bug	CAMHD	Bug: "Progress Notes Associated to Invoices" page not loading	3 3 - Medium PROD	3/31/2023 17:11
35278 E	3ug	DDD	Bug - Cal3.0 - BiMonthly Recurrence authorization not taking into account Unit of Service	2 3 - Medium PROD	6/3/2024 11:53
35317 E	3ug	DDD	DDD - Plan Services with no Provider Plan	2 3 - Medium PROD	6/24/2024 9:06
35450 E	Bug	DDD	DDD - Calculator not printing correctly	2 3 - Medium PROD	7/26/2024 8:36
36383 E	Зug	DDD	DDD - Calculator problem with paid base and add on	2 3 - Medium PROD	9/26/2024 9:19
36854 E	Зug	DDD	DDD - Inspire - backed up ISP in the wrong place	1 3 - Medium PROD	10/31/2024 3:13
37186 E	Зug	Both	Both - "On deactivation of Plan Service - deactivate related Provider Plan Service Flow" issue	1 3 - Medium PROD	12/6/2024 9:10
37387 E	Зug	DDD	DDD - C3.0 - MYC New Service Details Not Appearing	2 3 - Medium PROD	12/16/2024 8:30
37388 E	3ug 🛛	DDD	DDD - C3.0 - Change of Provider One Time Authorizations Not Splitting Units	2 3 - Medium PROD	12/16/2024 8:33
37599 E	Зug	DDD	DDD - Provider cannot submit an AER due to duration error	2 3 - Medium PROD	1/15/2025 10:52
37663 E	Зug	DDD	Data Update to Account for Missing Provider Plan Value on Plan Service	1 3 - Medium PROD	1/23/2025 8:01
37694 E	Зug	DDD	DDD - TCM batch file date is different in PROD from other environments	2 3 - Medium PROD	1/29/2025 8:25
37793 E	Зug	DDD	DDD - ISP Report Generation Issues	2 3 - Medium PROD	2/10/2025 10:06
37805 E	Зug	Both	Both - Provider Portal Issues Opening Up Customers in PROD	1 3 - Medium PROD	2/11/2025 7:34
37879 E	Зug	DDD	DDD - Provider Summary Report not displaying Customers in Provider Portal in PROD	1 3 - Medium PROD	2/19/2025 8:14
37733 E	Зug	DDD	DDD - Incorrect Columns displaying on Provider Plan subgrid (Action Plan tab of ISP)	1 3 - Medium PROD	2/5/2025 5:37
37791 E	Bug		DDD - CIT Referral: Create Document Location Flow Failures	2 3 - Medium PROD	2/10/2025 9:30





Solutions that Matter

	Short	Finding Statement	Analysis and Significance	Recommendation	Finding Update	Category	Туре	Priority	Status Clo	sed Date	Identified Date	Owner	
	Description			1 To serve offective Terrs beaking it is served for both di initiative P	2/20/25 Demonster Testing for D4.11 is set ad definer 2/25/2025 (***/2/2025	Test Practice	leave.	Medium	Open		12/21/2010	Gautam	
	Regression testing	As a result of regression testing not being consistently performed, production releases are breaking existing	R3.3 introduced a defect that deprecated features in production specific to Integrated Suppor and Life Trajectory functionality. DDD has informed IV&V that there are other examples of		2/28/25 - Regression Testing for R4.11 is scheduled from 3/25/2025 to 4/2/2025. CAMHD will perform both manual and automated tests, while DDD will focus exclusively		Issue	Medium	Open		12/31/2019	Gautam Gulvady	
ľ	testing	functionality in the production environment.	functionality being deprecated after a release, some of which are still being investigated. As of	open communication and consensus-building are essential for optimizing	on manual regression testing. To support future Phase 4 releases, including R4.11 and	Validation						Guivady	
		functionality in the production environment.	this report, IV&V has not evaluated the project's root cause analysis (RCA) process used to	tester utilization. By collaborating to prioritize testing efforts, share critical	beyond, the project will onboard a Tosca Automated Regression Testing SME, with the								
			determine why such functionality was deprecated but will discuss further with BHA in January		work set to begin on 3/10/2025. The SI has uploaded and executed one regression test								
			2020	comprehensive regression testing without overburdening a single resource.	case for the AER project and is preparing additional regression test scripts with estimated								
			Thorough vetting and validation of regression test cases are necessary to prevent defects	This collaborative approach will balance workloads, streamline processes, and									
			when a release is pushed live. When defects occur in production, the project should follow a	enhance test coverage, minimizing delays and bottlenecks. Ultimately, it will	completion before the next go me.								
			defined and repeatable process for determining the root cause of the problem.	enable both divisions to efficiently meet their testing objectives.	1/31/25 - Regression Testing for R4.10 is scheduled from 1/29/2025 to 2/5/2025. One								
			denned and repeatable process for determining the root could of the problem.	enable betranisions to enreently meet their testing objectives	defect (view on the DDD supervisor dashboard) has come out of regression testing.								
				2. A balanced approach that combines manual and automated regression	CAMHD will conduct a mix of manual and automated testing, while DDD will focus on								
				testing to ensure broad test coverage and flexibility.	manual regression testing. To support future Phase 4 releases beyond R4.10, the project								
				,	plans to onboard a Tosca automated regression testing Subject Matter Expert (SME). The								
				3. Having board(s) in Azure DevOps or a document on SharePoint that	plans and timeline for Tosca automated regression testing are being reviewed, with plans								
				provides information about the status of regression testing automation, to	to commence work on 3/1/2025. For the AER project, the SI is preparing to conduct								
				facilitate visibility and transparency to BHA project personnel and	regression testing on AER functionality.								
				stakeholders.									
					12/31/24 - R4.9 regression testing was conducted manually from 11/25/2024 to								
				4. IV&V recommends reevaluating the schedule priorities by distributing the	12/4/2024, identifying one (1) defect. However, users encountered three (3) production								
				work according to the resource bandwidth. This will ensure that the schedule	defects in R4.9. IV&V remains concerned about the exclusive reliance on manual								
				is not impacted and that the work is done efficiently between regression	regression testing, which poses risks such as inefficiencies, human error, limited test								
				testing and Golden Record (GR).	coverage, and dependency on specific testers. IV&V recommends investing in automated								
				Contraction of Londy.	regression testing to enhance efficiency, reduce the burden on BHA staff, and improve								
				5. Pursue and complete additional formal training in Azure DevOps and	product quality.								
				Tricentis for test automation as soon and complete efforts to automate the	For R4.10, regression testing is planned for 1/29/2025-2/5/2025, with CAMHD utilizing								
				two primary regression test scripts.	TOSCA for automated regression testing and DDD relying solely on manual testing.								
				two printing regression test scripts.	reserver of automated regression testing and bob reiving solely of mandar testing.								
				6. IV&V recommends DDD and CAMHD to develop a common and consistent	11/30/2024 - For the 3rd consecutive release (releases 4.7 through 4.9), regression								
				approach across divisions for performing regression testing.	testing is being done solely manually. Relying solely on manual regression testing without								
				approximations and bring the performing regression costing.	any automation could introduce risks and inefficiencies such as increased time and effort								
				7 Determine if current regression testing timeframes are adequate and if not	that may lead to delays, human error, inconsistencies as testing outcomes can vary								
				add more time to the pre-production regression test efforts for all release	depending on the individual tester, limited test coverage, risk of production defects since								
				deployments.	manual testing is prone to human error and the likelihood of defects slipping through to								
4	Code quality	Due to multiple quality concerns, the project may continue to	System defects identified in August that affected claims were due to multi-faceted quality	IV&V recommends:	2/28/25 - R4.10 was deployed to production on 2/6/2025. That same day, users reported	Project Management	Issue	Medium	Onen		9/30/2020	Gautam	
	,	face impactful system defects.	issues were individually addressed during this reporting period. IV&V notes that there is one	1. Closer collaboration between divisions to review reported defects, ensuring	a critical defect, prompting the deployment of a hotfix with a workaround on 2/7/2025.						-,,	Gulvadv	
			remaining defect still being evaluated that affects a limited number of claims. Overall, the		Following the deployment of R4.10, the project has recorded five additional unresolved								
			Project Team has responded with a commitment to increase project quality and is in the	priority of production defects.	production defects: two high severity, two medium severity, and one low severity, in								
			process of identifying improvements to associated testing processes. These currently include:	phoney of production derects.	Azure DevOps (ADO)—(see Appendix E for details). BHA is prioritizing higher-priority								
			Performing Revenue Neutrality Testing to ensure expected revenue streams are largely	2. The project utilize tools such as SonarQube for continuous inspection of	tasks, which has delayed addressing these lower-priority defects, though remediation								
			unchanged from one period to the next. Conducting System Integration Testing, User	code quality and establishing a source code quality threshold to maintain high-									
			Acceptance Testing, Performance Testing, and Regression Testing for Release 3.10. IV&V will	guality, secure, and maintainable code.									
			continue to monitor the testing efforts throughout the balance of Release 3.10 and validate	quanty, secure, and maintainable code.	Sprint Deployment (MSD) with 2 new items were deployed the same day. The R4.11 go- live is scheduled for 4/3/2025. IV&V remains concerned about code guality and will								
			continue to monitor the testing efforts throughout the balance of Release 3.10 and validate that enhanced quality processes, including industry standard regression testing, continue for		live is scheduled for 4/3/2025. IV&V remains concerned about code quality and will								
			that enhanced quality processes, including industry standard regression testing, continue for	3. The project increases comprehensive testing prior to joint testing to reduce	live is scheduled for 4/3/2025. IV&V remains concerned about code quality and will								
			that enhanced quality processes, including industry standard regression testing, continue for Agile Release 3.11 forward. Finally, IV&V reviewed and provided feedback on the Help Desk		live is scheduled for 4/3/2025. IV&V remains concerned about code quality and will continue to monitor R4.10, FHIR, any MSDs, and the AER solution.								
			that enhanced quality processes, including industry standard regression testing, continue for Agile Release 3.11 forward. Finally, IV&V reviewed and provided feedback on the Help Desk and Semantic Layer design documents per request and found that both documents lacked	 The project increases comprehensive testing prior to joint testing to reduce the burden on BHA testers and reduce post-production defects. 	live is scheduled for 4/3/2025. IV&V remains concerned about code quality and will continue to monitor R4.10, FHIR, any MSDs, and the AER solution. 1/31/25 - The R4.10 go-live is scheduled for 2/6/2025. Currently, 25 unresolved								
			that enhanced quality processes, including industry standard regression testing, continue for Agile Release 3.11 forward. Finally, IV&V reviewed and provided feedback on the Help Desk and Semantic Layer design documents per request and found that both documents lacked design details.	The project increases comprehensive testing prior to joint testing to reduce the burden on BHA testers and reduce post-production defects. A. The Si vendor add a "Found In" column to the daily scrum file to indicate	live is scheduled for 4/3/2025. IV&V remains concerned about code quality and will continue to monitor R4.10, FHIR, any MSDs, and the AER solution. 1/31/25 - The R4.10 go-live is scheduled for 2/6/2025. Currently, 25 unresolved production defects remain, including (refer to Appendix E for a list of unresolved								
			that enhanced quality processes, including industry standard regression testing, continue for Agile Release 3.11 forward. Finally, IV&V reviewed and provided feedback on the Help Desk and Semantic Layer design documents per request and found that both documents lacked design details. The identified quality issues have negatively affected DOH billing processes and DOH has	 The project increases comprehensive testing prior to joint testing to reduce the burden on BHA testers and reduce post-production defects. 	live is scheduled for 4/3/2025. IV&V remains concerned about code quality and will continue to monitor R4.10, FHR, any MSDs, and the AER solution. 1/31/25 - The R4.10 go-live is scheduled for 2/c/2025. Currently, 25 unresolved production defects remain, including (refer to Appendix E for a list of unresolved production defects). The SI indicated that BHA prioritizes higher-priority tasks, delaying								
			that enhanced quality processes, including industry standard regression testing, continue for Agile Release 3.11 forward. Finally, IV&V reviewed and provided feedback on the Help Desk and Semantic Layer design documents per request and found that both documents lacked design details.	The project increases comprehensive testing prior to joint testing to reduce the burden on BHA testers and reduce post-production defects. The Si vendor add a "Found In" column to the daily scrum file to indicate the environment where each defect was identified.	live is scheduled for 4/2/2025. IV&V remains concerned about code quality and will continue to monitor R4.10, FHIR, any MSDs, and the AER solution. 1/31/25 - The R4.10 go-live is scheduled for 2/6/2025. Currently, 25 unresolved production defects remain, including (refer to Appendix E for a list of unresolved production defects). The 51 indicated that BHA prioritizes higher-priority tasks, delaying the resolution of lower-priority defects. Efforts are underway to address these issues. The								
			that enhanced quality processes, including industry standard regression testing, continue for Agile Release 3.11 forward. Finally, IV&V reviewed and provided feedback on the Help Desk and Semantic Layer design documents per request and found that both documents lacked design details. The identified quality issues have negatively affected DOH billing processes and DOH has	The project increases comprehensive testing prior to joint testing to reduce the burden on BHA testers and reduce post-production defects. A. The SI vendor add a "Found In" column to the daily scrum file to indicate the environment where each defect was identified. S. The SI vendor provides the total number of defects in production and	live is scheduled for 4/3/2025. IV&V remains concerned about code quality and will continue to monitor R4.10, FHIR, any MSDs, and the AER solution. 1/31/25 - The R4.10 go-live is scheduled for 2/6/2025. Currently, 25 unresolved production defects remain, including (refer to Appendix E for a list of unresolved production defects). The SI indicated that BHA prioritizes higher-priority tasks, delaying the resolution of lower-priority defects. Efforts are underway to address these issues. The FIRI development was completed and deployed to production on 1/29/25. with delays								
			that enhanced quality processes, including industry standard regression testing, continue for Agile Release 3.11 forward. Finally, IV&V reviewed and provided feedback on the Help Desk and Semantic Layer design documents per request and found that both documents lacked design details. The identified quality issues have negatively affected DOH billing processes and DOH has	The project increases comprehensive testing prior to joint testing to reduce the burden on BHA testers and reduce post-production defects. The Si vendor add a "Found In" column to the daily scrum file to indicate the environment where each defect was identified.	live is scheduled for 4/3/2025. /V&V remains concerned about code quality and will continue to monitor R4.10, FHIR, any MSDs, and the AER solution. 1/31/25 - The R4.10 go-live is scheduled for 2/6/2025. Currently, 25 unresolved production defects remain, including (refer to Appendix E for a list of unresolved production defects). The 51 indicated that BHA prioritizes higher-priority tasks, delaying the resolution of lower-priority defects. Efforts are underway to address these issues. The FHIR development was completed and deployed to production on 1/29/25, with delayi due to issues related to integrating with Microsoft and Apple Health. The AER solution go								
			that enhanced quality processes, including industry standard regression testing, continue for Agile Release 3.11 forward. Finally, IV&V reviewed and provided feedback on the Help Desk and Semantic Layer design documents per request and found that both documents lacked design details. The identified quality issues have negatively affected DOH billing processes and DOH has	3. The project increases comprehensive testing prior to joint testing to reduce the burden on BHA testers and reduce post-production defects. 4. The SI vendor add a "Found In" column to the daily scrum file to indicate the environment where each defect was identified. 5. The SI vendor provides the total number of defects in production and reports these numbers regularly to BHA.	live is scheduled for 4/3/2025. IV&V remains concerned about code quality and will continue to monitor R4.10, FHIR, any MSDs, and the AER solution. 1/31/25 - The R4.10 go-live is scheduled for 2/6/2025. Currently, 25 unresolved production defects; Thes 1 indicated that BHA prioritizes higher-priority tasks, delaying the resolution of lower-priority defects. Efforts are underway to address these issues. The FHIR development was completed and deployed to production on 1/29/25, with delays due to issues related to integrating with Microsoft and Apple Health. The AER solution go live is scheduled for 2/21/2025. VKW will continue to monitor the quality of both R4.10.								
			that enhanced quality processes, including industry standard regression testing, continue for Agile Release 3.11 forward. Finally, IV&V reviewed and provided feedback on the Help Desk and Semantic Layer design documents per request and found that both documents lacked design details. The identified quality issues have negatively affected DOH billing processes and DOH has	3. The project increases comprehensive testing prior to joint testing to reduce the burden on BHA testers and reduce post-production defects. 4. The SI vendor add a "Found In" column to the daily scrum file to indicate the environment where each defect was identified. 5. The SI vendor provides the total number of defects in production and reports these numbers regularly to BHA. 6. The project evaluate existing project staff skills and experience level to	live is scheduled for 4/3/2025. /V&V remains concerned about code quality and will continue to monitor R4.10, FHIR, any MSDs, and the AER solution. 1/31/25 - The R4.10 go-live is scheduled for 2/6/2025. Currently, 25 unresolved production defects remain, including (refer to Appendix E for a list of unresolved production defects). The 51 indicated that BHA prioritizes higher-priority tasks, delaying the resolution of lower-priority defects. Efforts are underway to address these issues. The FHIR development was completed and deployed to production on 1/29/25, with delayi due to issues related to integrating with Microsoft and Apple Health. The AER solution go								
			that enhanced quality processes, including industry standard regression testing, continue for Agile Release 3.11 forward. Finally, IV&V reviewed and provided feedback on the Help Desk and Semantic Layer design documents per request and found that both documents lacked design details. The identified quality issues have negatively affected DOH billing processes and DOH has	3. The project increases comprehensive testing prior to joint testing to reduce the burden on BHA testers and reduce post-production defects. 4. The SI vendor add a "Found In" column to the daily scrum file to indicate the environment where each defect was identified. 5. The SI vendor provides the total number of defects in production and reports these numbers regularly to BHA.	live is scheduled for 4/3/2025. /V&V remains concerned about code quality and will continue to monitor R4.10, FHIR, any MSDs, and the AER solution. 1/31/25 - The R4.10 go-live is scheduled for 2/6/2025. Currently, 25 unresolved production defects remain, including (refer to Appendix E for a list of unresolved production defects). The 51 indicated that BHA prioritizes higher-priority tasks, delaying the resolution of lower-priority defects. Efforts are underway to address these issues. The FHIR development was completed and deployed to production on 1/29/25, with delays due to issues related to integrating with Microsoft and Apple Health. The AER solution go live is scheduled for 2/21/2025. /V&V will continue to monitor the quality of both R4.10, FHIR, any MSDs, and the AER solution.								
			that enhanced quality processes, including industry standard regression testing, continue for Agile Release 3.11 forward. Finally, IV&V reviewed and provided feedback on the Help Desk and Semantic Layer design documents per request and found that both documents lacked design details. The identified quality issues have negatively affected DOH billing processes and DOH has	The project increases comprehensive testing prior to joint testing to reduce the burden on BHA testers and reduce post-production defects. A. The SI vendor add a "Found In" column to the daily scrum file to indicate the environment where each defect was identified. S. The SI vendor provides the total number of defects in production and reports these numbers regularly to BHA. F. The project evaluate existing project staff skills and experience level to ensure they meet BHA support requirements.	live is scheduled for 4/3/2025. IV&V remains concerned about code quality and will continue to monitor R4.10, FHIR, any MSDs, and the AER solution. 1/31/25 - The R4.10 go-live is scheduled for 2/6/2025. Currently, 25 unresolved production defects remain, including (refer to Appendix E for a list of unresolved production defects). The S1 indicated that BHA prioritizes higher-priority tasks, delaying the resolution of lower-priority defects. Efforts are underway to address these issues. The FHIR development was completed and deployed to production on 1/2/22, with delays due to issues related to integrating with Microsoft and Apple Health. The AER solution go live is scheduled for 2/21/2025. IV&V will continue to monitor the quality of both R4.10, FHIR, any MSDs, and the AER solution. 12/31/24 - R4.9 was deployed to production on 12/5/2024, with successful smoke								
			that enhanced quality processes, including industry standard regression testing, continue for Agile Release 3.11 forward. Finally, IV&V reviewed and provided feedback on the Help Desk and Semantic Layer design documents per request and found that both documents lacked design details. The identified quality issues have negatively affected DOH billing processes and DOH has	The project increases comprehensive testing prior to joint testing to reduce the burden on BHA testers and reduce post-production defects. The Si vendor add a "Found In" column to the daily scrum file to indicate the environment where each defect was identified. S. The Si vendor provides the total number of defects in production and reports these numbers regularly to BHA. S. The project evaluate existing project staff skills and experience level to ensure they meet. BHA support requirements. T. The project perform CAMHD revenue neutrality fiscal balance testing on a	live is scheduled for 4/2/2025. IV&V remains concerned about code quality and will continue to monitor R4.10, FHIR, any MSDs, and the AER solution. 1/31/25 - The R4.10 go-live is scheduled for 2/6/2025. Currently, 25 unresolved production defects remain, including (refer to Appendix E for a list of unresolved production defects). The 51 indicated that BHA prioritizes higher-priority tasks, delaying the resolution of lower-priority defects. Efforts are underway to address these issues. The FHIR development was completed and deployed to production on 1/29/25, with delays due to issues related to integrating with Microsoft and Apple Health. The AER solutions live is scheduled for 27/21/2025. IV&V will continue to monitor the quality of both R4.10, FHIR, any MSDs, and the AER solution. 12/31/24 - R4.9 was deployed to production on 12/5/2024, with successful smoke testing completed on on 12/6/2024. A mid-sprint deployment with two (2) user stories								
			that enhanced quality processes, including industry standard regression testing, continue for Agile Release 3.11 forward. Finally, IV&V reviewed and provided feedback on the Help Desk and Semantic Layer design documents per request and found that both documents lacked design details. The identified quality issues have negatively affected DOH billing processes and DOH has	The project increases comprehensive testing prior to joint testing to reduce the burden on BHA testers and reduce post-production defects. A. The SI vendor add a "Found In" column to the daily scrum file to indicate the environment where each defect was identified. S. The SI vendor provides the total number of defects in production and reports these numbers regularly to BHA. F. The project evaluate existing project staff skills and experience level to ensure they meet BHA support requirements.	live is scheduled for 4/3/2025. IV&V remains concerned about code quality and will continue to monitor R4.10, FHIR, any MSDs, and the AER solution. 1/31/25 - The R4.10 go-live is scheduled for 2/6/2025. Currently, 25 unresolved production defects remain, including (refer to Appendix E for a list of unresolved production defects; The 51 indicated that BHA prioritizes higher-priority tasks, delaying the resolution of lower-priority defects. Efforts are underway to address these issues. The FHIR development was completed and deployed to production on 1/29/25, with delays due to issues related to integrating with Microsoft and Apple Health. The AER solution go live is scheduled for 2/21/2025. IV&V will continue to monitor the quality of both R4.10, FHIR, any MSDs, and the AER solution. 12/31/24 - R4.9 was deployed to production on 12/5/2024, with successful smoke testing completed on 12/6/2024. A mid-spirit deployment with two (2) user stories followed on 12/16/2024. Currently, 19 production defects remain unresolved (18								
			that enhanced quality processes, including industry standard regression testing, continue for Agile Release 3.11 forward. Finally, IV&V reviewed and provided feedback on the Help Desk and Semantic Layer design documents per request and found that both documents lacked design details. The identified quality issues have negatively affected DOH billing processes and DOH has	The project increases comprehensive testing prior to joint testing to reduce the burden on BHA testers and reduce post-production defects. The Si vendor add a "Found In" column to the daily scrum file to indicate the environment where each defect was identified. S. The Si vendor provides the total number of defects in production and reports these numbers regularly to BHA. C. The project evaluate existing project staff skills and experience level to ensure they meet BHA support requirements. The project perform CAMHD revenue neutrality fiscal balance testing on a quarterly basis to ensure revenues are as expected.	live is scheduled for 4/2/2025. /V&V remains concerned about code quality and will continue to monitor R4.10, FHIR, any MSDs, and the AER solution. 1/31/25 - The R4.10 go-live is scheduled for 2/6/2025. Currently, 25 unresolved production defects remain, including (refer to Appendix E for a list of unresolved production defects remain, including (refer to Appendix E for a list of unresolved production defects remain, including (refer to Appendix E for a list of unresolved production defects remain, including (refer to Appendix E for a list of unresolved production defects remain, including (refer to Appendix E for a list of unresolved production defects). The 51 indicated that BHA prioritizes higher-priority tasks, delaying the resolution of lower-priority defects. Efforts are underway to address these issues. The FHIR development was completed and deployed to production on 1/29/25, with delays due to issues related to integrating with Microsoft and Apple Health. The AER solutions 12/31/24 - R4.9 was deployed to production on 12/5/2024, with successful smoke testing completed on 12/6/2024. A mid-sprint deployment with two (2) user stories followed on 12/16/2024. Currently, 19 production defects remain unresolved (18 medium severity, 11 pils sverity) despite through testing. The S1 stated that BHA								
			that enhanced quality processes, including industry standard regression testing, continue for Agile Release 3.11 forward. Finally, IV&V reviewed and provided feedback on the Help Desk and Semantic Layer design documents per request and found that both documents lacked design details. The identified quality issues have negatively affected DOH billing processes and DOH has	The project increases comprehensive testing prior to joint testing to reduce the burden on BHA testers and reduce post-production defects. The SI vendor add a "Found In" column to the daily scrum file to indicate the environment where each defect was identified. The SI vendor provides the total number of defects in production and reports these numbers regularly to BHA. The SI vendor provides the total number of defects in production and reports these numbers regularly to BHA. The project evaluate existing project staff skills and experience level to ensure they meet BHA support requirements. The project perform CAMHD revenue neutrality fiscal balance testing on a quarterly basis to ensure revenues are as expected. The project assign dedicated resources to provide oversight of CAMHD	live is scheduled for 4/3/2025. IV&V remains concerned about code quality and will continue to monitor R4.10, FHIR, any MSDs, and the AER solution. 1/31/25 - The R4.10 go-live is scheduled for 2/6/2025. Currently, 25 unresolved production defects; Thes 1 indicated that BHA prioritizes higher-priority tasks, delaying the resolution of lower-priority defects. Efforts are underway to address these issues. The FHIR development was completed and deployed to production on 1/29/25, with delays due to issues related to integrating with Microsoft and Apple Health. The AER solution go live is scheduled for 2/21/2025. FVX will continue to monitor the quality of both R4.10, FHIR, any MSDs, and the AER solution. 12/31/24 - R4.9 was deployed to production on 12/5/2024, with successful smoke testing completed on 12/6/2024. Currently, 19 production defects remain unresolved (18 medium severity, 1 high severity) despite through testing. The S1 stated that BHA prioritizes higher-priority tasks, leaving lower-priority defects unaddresed. The S1 is to site advection the state that BHA prioritizes higher-priority tasks, leaving lower-priority defects unaddresed. The S1 is to prioritizes higher-priority tasks, leaving lower-priority defects unaddresed. The S1 stated that BHA prioritizes higher-priority tasks, leaving lower-priority defects unaddresed. The S1 is the state that BHA prioritizes higher-priority tasks, leaving lower-priority defects unaddresed. The S1 is the state that BHA prioritizes higher-priority tasks, leaving lower-priority								
			that enhanced quality processes, including industry standard regression testing, continue for Agile Release 3.11 forward. Finally, IV&V reviewed and provided feedback on the Help Desk and Semantic Layer design documents per request and found that both documents lacked design details. The identified quality issues have negatively affected DOH billing processes and DOH has	The project increases comprehensive testing prior to joint testing to reduce the burden on BHA testers and reduce post-production defects. The Si vendor add a "Found In" column to the daily scrum file to indicate the environment where each defect was identified. S. The Si vendor provides the total number of defects in production and reports these numbers regularly to BHA. C. The project evaluate existing project staff skills and experience level to ensure they meet BHA support requirements. The project perform CAMHD revenue neutrality fiscal balance testing on a quarterly basis to ensure revenues are as expected.	live is scheduled for 4/2/2025. IV&V remains concerned about code quality and will continue to monitor R4.10, FHIR, any MSDs, and the AER solution. 1/31/25 - The R4.10 go-live is scheduled for 2/6/2025. Currently, 25 unresolved production defects remain, including (refer to Appendix E for a list of unresolved production defects remain, including (refer to Appendix E for a list of unresolved production defects remain, including (refer to Appendix E for a list of unresolved production defects remain, including (refer to Appendix E for a list of unresolved production defects remain, including (refer to Appendix E for a list of unresolved production defects). The 51 indicated that BHA prioritizes higher-priority tasks, delaying the resolution of lower-priority defects. Efforts are underway to address these issues. The FHIR development was completed and deployed to production on 1/29/25, with delays due to issues related to integrating with Microsoft and Apple Health. The AER solution glive is scheduled for 2/21/2025. IV&V will continue to monitor the quality of both R4.10, FHIR, any MSDs, and the AER solution. 12/31/24 - R4.9 was deployed to production on 12/5/2024, with successful smoke testing completed on 12/6/2024. A mid-sprint deployment with two (2) user stories followed on 12/6/2024. Currently, 19 production defects remain unresolved (18 medium severity, 11 high severity lobagint through testing. The S1 stated that BHA prioritizes higher-priority tasks, leaving lower-priority defects unaddressed. The S1 is working to resolve these issues. (IVA) wall BHA remain concerned about conging code								
			that enhanced quality processes, including industry standard regression testing, continue for Agile Release 3.11 forward. Finally, IV&V reviewed and provided feedback on the Help Desk and Semantic Layer design documents per request and found that both documents lacked design details. The identified quality issues have negatively affected DOH billing processes and DOH has	The project increases comprehensive testing prior to joint testing to reduce the burden on BHA testers and reduce post-production defects. The Si vendor add a "Found In" column to the daily scrum file to indicate the environment where each defect was identified. The Si vendor provides the total number of defects in production and reports these numbers regularly to BHA. The project evaluate existing project staff skills and experience level to ensure they meet BHA support requirements. The project perform CAMHD revenue neutrality fiscal balance testing on a quarterly basis to ensure revenues are as expected. The project asign dedicated resources to provide oversight of CAMHD Fiscal Processes.	live is scheduled for 4/2/2025. IV&V remains concerned about code quality and will continue to monitor R4.10, FHIR, any MSDs, and the AER solution. 1/31/25 - The R4.10 go-live is scheduled for 2/6/2025. Currently, 25 unresolved production defects remain, including (refer to Appendix E for a list of unresolved production defects). The 51 indicated that BHA prioritizes higher-priority tasks, delaying the resolution of lower-priority defects. Efforts are underway to address these issues. The FHIR development was completed and deployed to production on 1/29/25, with delays due to issues related to integrating with Microsoft and Apple Health. The AER solution priority of the scheduled for 2/21/2025. IV&V will continue to monitor the quality of both R4.10, FHIR, any MSDs, and the AER solution. 12/31/24 - R4.9 was deployed to production on 12/5/2024, with successful smoke testing completed on 12/6/2024. Currently, 19 production defects remain unresolved (18 medium severity, 1 high severity), despite thorough testing. The Si stated that BHA prioritizes higher-priority tasks, leaving lower-priority defects unaddressed. The Si is working to resolve these issues, IV&V and BHA remain concerned about ongoing code quality problems and ther impact on users. BHA is considering utilizing todi such as								
			that enhanced quality processes, including industry standard regression testing, continue for Agile Release 3.11 forward. Finally, IV&V reviewed and provided feedback on the Help Desk and Semantic Layer design documents per request and found that both documents lacked design details. The identified quality issues have negatively affected DOH billing processes and DOH has	The project increases comprehensive testing prior to joint testing to reduce the burden on BHA testers and reduce post-production defects. The SI vendor add a "Found In" column to the daily scrum file to indicate the environment where each defect was identified. The SI vendor provides the total number of defects in production and reports these numbers regularly to BHA. The SI vendor provides the total number of defects in production and reports these numbers regularly to BHA. The project evaluate existing project staff skills and experience level to ensure they meet BHA support requirements. The project perform CAMHD revenue neutrality fiscal balance testing on a quarterly basis to ensure revenues are as expected. The project assign dedicated resources to provide oversight of CAMHD	live is scheduled for 4/2/2025. IV&V remains concerned about code quality and will continue to monitor R4.10, FHIR, any MSDs, and the AER solution. 1/31/25 - The R4.10 go-live is scheduled for 2/6/2025. Currently, 25 unresolved production defects remain, including (refer to Appendix E for a list of unresolved production defects remain, including (refer to Appendix E for a list of unresolved production defects remain, including (refer to Appendix E for a list of unresolved production defects remain, including (refer to Appendix E for a list of unresolved production defects remain, including (refer to Appendix E for a list of unresolved production defects). The 51 indicated that BHA prioritizes higher-priority tasks, delaying the resolution of lower-priority defects. Efforts are underway to address these issues. The FHIR development was completed and deployed to production on 1/29/25, with delays due to issues related to integrating with Microsoft and Apple Health. The AER solution glive is scheduled for 2/21/2025. IV&V will continue to monitor the quality of both R4.10, FHIR, any MSDs, and the AER solution. 12/31/24 - R4.9 was deployed to production on 12/5/2024, with successful smoke testing completed on 12/6/2024. A mid-sprint deployment with two (2) user stories followed on 12/6/2024. Currently, 19 production defects remain unresolved (18 medium severity, 11 high severity lobagint through testing. The S1 stated that BHA prioritizes higher-priority tasks, leaving lower-priority defects unaddressed. The S1 is working to resolve these issues. (IVA) wall BHA remain concerned about conging code								
			that enhanced quality processes, including industry standard regression testing, continue for Agile Release 3.11 forward. Finally, IV&V reviewed and provided feedback on the Help Desk and Semantic Layer design documents per request and found that both documents lacked design details. The identified quality issues have negatively affected DOH billing processes and DOH has	The project increases comprehensive testing prior to joint testing to reduce the burden on BHA testers and reduce post-production defects. The Si vendor add a "Found In" column to the daily scrum file to indicate the environment where each defect was identified. S. The Si vendor provides the total number of defects in production and reports these numbers regularly to BHA. The project evaluate existing project staff skills and experience level to ensure they meet BHA support requirements. The project perform CAMHD revenue neutrality fiscal balance testing on a quarterly basis to ensure revenues are as expected. The project asign dedicated resources to provide oversight of CAMHD Fiscal Processes. O. The project monitor implemented improvements for effectiveness.	live is scheduled for 4/2/2025. IV&V remains concerned about code quality and will continue to monitor R4.10, FHIR, any MSDs, and the AER solution. 1/31/25 - The R4.10 go-live is scheduled for 2/6/2025. Currently, 25 unresolved production defects remain, including (refer to Appendix E for a list of unresolved production defects.) The 51 indicated that BHA prioritizes higher-priority tasks, delaying the resolution of lower-priority defects. Efforts are underway to address these issues. The FHIR development was completed and deployed to production on 1/29/25, with delays due to issues related to integrating with Microsoft and Apple Health. The AER solutions plive is scheduled for 2/21/2025. IV&V will continue to monitor the quality of both R4.10, FHIR, any MSDs, and the AER solution. 12/31/24 - R4.9 was deployed to production on 12/5/2024, with successful smoke testing completed on 12/6/2024. A mid-sprint deployment with two (2) user stories followed on 12/16/2024. Currently, 19 production defects remain unresolved (18 medium severity, 11 high severity logispite throngy heating. The S1 stated that BHA prioritizes higher-priority tasks, leaving lower-priority defects unaddressed. The S1 is working to resolve these issues, IV&V and BHA remain concerned about ongoing code quality problems and their impact on users. BHA is considering utilizing tools such as SonarQube for continuous inspection and improvement of code quality.								
			that enhanced quality processes, including industry standard regression testing, continue for Agile Release 3.11 forward. Finally, IV&V reviewed and provided feedback on the Help Desk and Semantic Layer design documents per request and found that both documents lacked design details. The identified quality issues have negatively affected DOH billing processes and DOH has	The project increases comprehensive testing prior to joint testing to reduce the burden on BHA testers and reduce post-production defects. The Si vendor add a "Found In" column to the daily scrum file to indicate the environment where each defect was identified. S. The Si vendor provides the total number of defects in production and reports these numbers regularly to BHA. S. The project evaluate existing project staff skills and experience level to ensure they meet BHA support requirements. The project proferm CAMHD revenue neutrality fiscal balance testing on a quarterly basis to ensure revenues are as expected. S. The project saign dedicated resources to provide oversight of CAMHD Fiscal Processes. D. The projects monitor implemented improvements for effectiveness. 10. Performing an RCA in collaboration with RSM after all future release	live is scheduled for 4/2/2025. IV&V remains concerned about code quality and will continue to monitor R4.10, FHIR, any MSDs, and the AER solution. 1/31/25 - The R4.10 go-live is scheduled for 2/6/2025. Currently, 25 unresolved production defects remain, including (refer to Appendix E for a list of unresolved production defects is the link of the transmission of the transmission of the solution of lower-priority detects. Efforts are underway to address these issues. The FHIR development was completed and deployed to production on 1/29/25, with delays due to issues related to integrating with Microsoft and Apple Health. The AER solutions live is scheduled for 2/21/2025. IV&V will continue to monitor the quality of both R4.10, FHIR, any MSDs, and the AER solution. 12/31/24 - R4 was deployed to production on 12/5/2024, with successful smoke testing completed on 12/6/2024. Currently, 19 production defects remain uncreaved (18 medium severity) 1 high severity) despite thorough testing. The S1 stated that BHA prioritizes higher-priority tasks, leaving lower-priority defects unaddressed. The S1 is working to resolve these issues, IV&V and BHA remain concerned about ongoing code quality problems and the impact on users. BHA is considering utilizing tools such as SonarQube for continuous inspection and improvement of code quality. 11/30/2024 - R4.9 is scheduled to be deployed to production on 12/5/2024. In the								
			that enhanced quality processes, including industry standard regression testing, continue for Agile Release 3.11 forward. Finally, IV&V reviewed and provided feedback on the Help Desk and Semantic Layer design documents per request and found that both documents lacked design details. The identified quality issues have negatively affected DOH billing processes and DOH has	The project increases comprehensive testing prior to joint testing to reduce the burden on BHA testers and reduce post-production defects. The Si vendor add a "Found In" column to the daily scrum file to indicate the environment where each defect was identified. S. The Si vendor provides the total number of defects in production and reports these numbers regularly to BHA. The project evaluate existing project staff skills and experience level to ensure they meet BHA support requirements. The project perform CAMHD revenue neutrality fiscal balance testing on a quarterly basis to ensure revenues are as expected. The project asign dedicated resources to provide oversight of CAMHD Fiscal Processes. O. The project monitor implemented improvements for effectiveness.	live is scheduled for 4/2/2025. IV&V remains concerned about code quality and will continue to monitor R4.10, FHIR, any MSDs, and the AER solution. 1/31/25 - The R4.10 go-live is scheduled for 2/6/2025. Currently, 25 unresolved production defects remain, including (refer to Appendix E for a list of unresolved production defects.) The 51 indicated that BHA prioritizes higher-priority tasks, delaying the resolution of lower-priority defects. Efforts are underway to address these issues. The FHIR development was completed and deployed to production on 1/29/25, with delays due to issues related to integrating with Microsoft and Apple Health. The AER solutions plive is scheduled for 2/21/2025. IV&V will continue to monitor the quality of both R4.10, FHIR, any MSDs, and the AER solution. 12/31/24 - R4.9 was deployed to production on 12/5/2024, with successful smoke testing completed on 12/6/2024. A mid-sprint deployment with two (2) user stories followed on 12/16/2024. Currently, 19 production defects remain unresolved (18 medium severity, 11 high severity logispite throngy heating. The S1 stated that BHA prioritizes higher-priority tasks, leaving lower-priority defects unaddressed. The S1 is working to resolve these issues, IV&V and BHA remain concerned about ongoing code quality problems and their impact on users. BHA is considering utilizing tools such as SonarQube for continuous inspection and improvement of code quality.								

ID S	Short Description	Finding Statement	Analysis and Significance	Recommendation	Finding Update	Category	Туре	Priority	Status	Closed Date	Identified Date	Owner	
31 5	Sprint Demos	Lack of regular Sprint Reviews and Sprint Demos will likely	Earlier in the project, end-of-sprint demos were conducted. Sprint reviews/demos help to	According to Agile Best Practices, IV&V recommends including Sprint reviews	2/28/25 - CAMHD conducted a demo for stakeholders, receiving valuable feedback	Sprint Planning	Risk	Closed	Open	2/28/2025	7/26/2023	Gautam	
		lead to misalignments between delivered work and	bring alignment across the team and stakeholders. They are essential building blocks for better	and demos in future releases (R4.2 and onwards).	confirming the design aligned with business needs. It has been agreed that demos will be							Gulvady	
		stakeholder needs.	software and teams. Sprint demos /reviews showcase the main functionality to stakeholders		conducted on a case-by-case basis moving forward. DDD has actively involved key team								
			and incorporate their feedback. Currently, the project has joint testing involving the SI and	1. At the end of each sprint, conduct a sprint review meeting to demonstrate	members in joint testing sessions, which has ensured a more comprehensive review and								
			BHA personnel. Per Agile Best practices, IV&V believes having Sprint demos/reviews during a	the completed work to stakeholders and gather feedback. Use this feedback	provided diverse insights. This involvement helps identify potential issues early and								
			sprint helps clarify and validate design prior to testing, steer the team in the right direction,	to refine and reprioritize the product backlog. For a 2-month sprint, IV&V	enhances overall testing effectiveness. Additionally, DDD is assessing whether a sprint								
			and help to avoid big mistakes. This would also allow the testing team to focus solely on	recommends having more than one (1) demo during the sprint.	demo is necessary for the calculator functionality, but their current process is proving								
			testing, which is beneficial.		effective in meeting business requirements. As a result, IV&V has closed the risk.								
				Create a stakeholder register to identify all stakeholders. List their									
			Based on Agile Best Practices, Sprint Demos or reviews occur during a sprint with the		1/31/25 - The Sprint Reviews and Demos are currently being conducted ad hoc. In recent								
			development team, scrum master, and product owner and and gives all relevant stakeholders	plan appropriate stakeholder engagement.	discussions, the project team has proposed incorporating both the Calculator								
			the opportunity to assess the completion of user stories, review important metrics and		functionality and the "copy forward" functionality into the process. The SI demonstrated								
			outcomes, and confirm if the Sprint goal has been achieved. This approach would also help	3.Foster active participation from users and stakeholders during both Sprint	AER Analytics functionality in December 2024, and the demos have been valuable for								
			prioritize and prepare the backlog for the next Sprint.		DDD in validating requirements and expectations. Although DDD has worked through the								
				development and ensure that user needs are consistently met.	requirements, some INSPIRE discrepancies have emerged during joint testing meetings.								
			Regular Sprint Reviews and demos strengthen the collaboration between development teams		The upcoming Sprint Reviews and Demos will provide an opportunity to address these								
			and stakeholders by enhancing communication channels and validating project objectives and		discrepancies, align expectations, and refine the approach as they move forward. The								
			ensuring that sprint deliverables remain consistent with stakeholder requirements.	and Sprint Demos. Encourage teams to deliver concise and informative	project team is actively exploring how to integrate these new functionalities into the		1						
- 1				progress reports, including achievements, challenges, and plans. This will	reviews and demos to ensure a smooth and efficient process.		1				1	1	
			They are a great opportunity for the product owner, stakeholders, and the team to review	enhance stakeholder engagement and project transparency.			1				1		
			what's being delivered and receive feedback. This way, the team can gauge responses and		12/31/24 - IV&V was informed that sprint reviews and demos are currently conducted on		1						
			make observations earlier during development and not later during testing.	5. Institute a structured documentation process for both activities. Document	an ad hoc basis. To improve the process, the project is planning to incorporate the		1						
				key decisions, action items, and insights from each session to ensure	demonstration of Calculator functionality into sprint reviews and demos. This would		1						
			Celebrating the team's accomplishments is also an essential part of these demos. Moreover,	accountability and to support ongoing process improvement.	provide valuable visibility into the progress and help address ongoing issues with the		1						
			they are invaluable in steering the team in the right direction and avoiding big mistakes.		calculator and provider portal, which are identified as frequent problem areas.								
			It's interesting to note that the Sprint Demo could bring to light bugs such as R4.1 bug 34055		11/30/24 - The project has indicated that sprint reviews and demos are conducted on an								
			on the Portal, where the checkbox is on the left of the text.		ad hoc basis, depending on the completion of features. There are no regular meetings								
					scheduled for sprint reviews. Demos are typically performed informally, often through								
					quick conversations or screen sharing, based on the priority and readiness of the								
					features. This informal approach to demos may result in inconsistent feedback collection								
					and delayed issue identification, which can negatively impact the overall effectiveness of								
					the sprint, IV&V recommends that the SI vendor establish regular sprint reviews and								
3 5	System	Performance bottlenecks with the INSPIRE production	Performance issues have been identified that have the potential to impact the system's	IV&V recommends:	2/28/25 - Production system performance remains stable with no current issues;	Project Management	Issue	Low	Open		8/18/2023	Gautam	
	performance	environment may result in low productivity and poor user	functionality, user experience, and the overall reliability of the system. These performance	1. BHA and the SI explore optimization strategies, including enhancing	however, DDD has reported that test environments have significantly slowed down, a						-,,	Gulvadv	
ľ		experience.	issues warrant immediate attention and resolution.	infrastructure and database resources, improving network connectivity,	concern particularly evident during AER training. IV&V has reduced the risk rating to low.							,	
				balancing and scaling load, refining the test strategy, and increasing test									
			The last performance test was executed in June 2023 for Phase 3 releases (R3.x). ~800+ new	environment resources.	1/31/25 - Microsoft completed the DDD performance test and submitted its report,								
			User Story Points (USPs) have been developed since the last performance test execution.		showing similar results between MAX and INSPIRE. IV&V has received and reviewed the								
			oser story round (osr s) have been developed since the last performance test excedition.	2. BHA execute a performance test during the development of R4.6 (planned	performance test report. However, the Provider Portal's performance declined as user								
			Developmental Disability Division (DDD) personnel are encountering performance issues with		volume increased to 500 JV&V recommends conducting performance testing at least		1	1					
			Developmental Disability Division (DDD) personnel are encountering performance issues with	completion 5/20/2024), identifying test cases and scenarios that include both									
			re-assigning cases and opening the DDD - Contact Notes (Fiscal View - Complete) view.	completion 5/20/2024), identifying test cases and scenarios that include both DDD and CAMHD functionality, transactions/functionality that are	volume increased to 500. IV&V recommends conducting performance testing at least annually to ensure system stability.								
				completion 5/20/2024), identifying test cases and scenarios that include both	annually to ensure system stability.								
			re-assigning cases and opening the DDD - Contact Notes (Fiscal View - Complete) view.	completion 5/20/2024), identifying test cases and scenarios that include both DDD and CAMHD functionality, transactions/functionality that are performance intensive, e.g., calculator functionality	annually to ensure system stability. 12/31/24 - Microsoft conducted performance testing for CAMHD functionality (MAX and								
			re-assigning cases and opening the DDD - Contact Notes (Fiscal View - Complete) view.	completion 5/20/2024), identifying test cases and scenarios that include both DDD and CAMHD functionality, transactions/functionality that are performance intensive, e.g., calculator functionality 2. Conduct load and performance testing for each release that has significant	annually to ensure system stability. 12/31/24 - Microsoft conducted performance testing for CAMHD functionality (MAX and Provider Portal) with 100, 200, and 300 users and delivered the performance report.								
			re-assigning cases and opening the DDD - Contact Notes (Fiscal View - Complete) view.	completion 5/20/2024), identifying test cases and scenarios that include both DDD and CAMHD functionality, transactions/functionality that are performance intensive, e.g., calculator functionality	annually to ensure system stability. 12/31/24 - Microsoft conducted performance testing for CAMHD functionality (MAX and Provider Portal) with 100, 200, and 300 users and delivered the performance report. According to the report, response times for MAX and INSPIRE remained consistent during								
			re-assigning cases and opening the DDD - Contact Notes (Fiscal View - Complete) view.	completion 5/20/2024), identifying test cases and scenarios that include both DDD and CAMHO functionality: transactions/functionality that are performance intensive, e.g., calculator functionality 2. Conduct load and performance testing for each release that has significant new features/functionality, e.g., calculator-related transactions.	annually to ensure system stability. 12/31/24 - Microsoft conducted performance testing for CAMHD functionality (MAX and Provider Portal) with 100, 200, and 300 users and delivered the performance report. According to the report, response times for MAX and INSPIRE remained consistent during each test. However, volumes at 300 portal users exceeded 2x the current production								
			re-assigning cases and opening the DDD - Contact Notes (Fiscal View - Complete) view.	completion 5/20/2024), identifying test cases and scenarios that include both DDD and CAMHD functionality, transactions/functionality that are performance intensive, e.g., calculator functionality 2. Conduct load and performance testing for each release that has significant new features/functionality, e.g., calculator-related transactions. 3. Create a plan for comprehensive performance testing and address any	annually to ensure system stability. 12/31/24 - Microsoft conducted performance testing for CAMHD functionality (MAX and Provider Portal) with 100, 200, and 300 users and delivered the performance report. According to the report, response times for MAX and INSPIRE remained consistent during each test. However, volumes at 300 portal users exceeded 2x the current production load, which Microsoft attributed to the portal running in trial index. This caused								
			re-assigning cases and opening the DDD - Contact Notes (Fiscal View - Complete) view.	completion 5/20/2024), identifying test cases and scenarios that include both DDD and CAMHO functionality: transactions/functionality that are performance intensive, e.g., calculator functionality 2. Conduct load and performance testing for each release that has significant new features/functionality, e.g., calculator-related transactions.	annually to ensure system stability. 12/31/24 - Microsoft conducted performance testing for CAMHD functionality (MAX and Provider Portal) with 100, 200, and 300 users and delivered the performance report. According to the report, response times for MAX and MISPIRE remainded consistent during each test. However, volumes at 300 portal users exceeded 2x the current production load, which Microsoft attributed to the portal running in trial mode. This caused degraded response times once user volume surpassed 200. Microsoft plans to conduct								
			re-assigning cases and opening the DDD - Contact Notes (Fiscal View - Complete) view.	completion 5/20/2024), identifying test cases and scenarios that include both DDD and CAMHD functionality, transactions/functionality that are performance intensive, e.g., calculator functionality 2. Conduct load and performance testing for each release that has significant new features/functionality, e.g., calculator-related transactions. 3. Create a plan for comprehensive performance testing and address any performance bottlenecks.	annually to ensure system stability. 12/31/24 - Microsoft conducted performance testing for CAMHD functionality (MAX and Provider Portal) with 100, 200, and 300 users and delivered the performance report. According to the report, response times for MAX and INSPIRE remained consistent during each test. However, volumes at 300 portal users exceeded 2x the current production load, which Microsoft attributed to the portal running in trial index. This caused degraded response times once user volume surpassed 200. Microsoft plans to conduct another round of testing after the RA 9 deployment once the portal environment is								
			re-assigning cases and opening the DDD - Contact Notes (Fiscal View - Complete) view.	completion 5/20/2024), identifying test cases and scenarios that include both DDD and CAMHD functionality, transactions/functionality that are performance intensive, e.g., calculator functionality 2. Conduct load and performance testing for each release that has significant new features/functionality, e.g., calculator-related transactions. 3. Create a plan for comprehensive performance testing and address any performance bottlenecks. 4. Have the benchmark assessments done annually and implementation of	annually to ensure system stability. 12/31/24 - Microsoft conducted performance testing for CAMHD functionality (MAX and Provider Portal) with 100, 200, and 300 users and delivered the performance report. According to the report, response times for MAX and MISPIRE remained consistent during each test. However, volumes at 300 portal users exceeded 2x the current production load, which Microsoft attributed to the portal running in trial mode. This caused degraded response times once user volume surpassed 200. Microsoft plans to conduct another round of testing after the R4.9 deployment once the portal environment is switched to production mode. Additionally, Microsoft is performing performance testing								
			re-assigning cases and opening the DDD - Contact Notes (Fiscal View - Complete) view.	completion 5/20/2024), identifying test cases and scenarios that include both DDD and CAMHD functionality, transactions/functionality that are performance intensive, e.g., calculator functionality 2. Conduct load and performance testing for each release that has significant new features/functionality, e.g., calculator-related transactions. 3. Create a plan for comprehensive performance testing and address any performance bottlenecks.	annually to ensure system stability. 12/31/24 - Microsoft conducted performance testing for CAMHD functionality (MAX and Provider Portal) with 100, 200, and 300 users and delivered the performance report. According to the report, response times for MAX and INSPIE remained consistent during each test. However, volumes at 300 portal users exceeded 2x the current production load, which Microsoft attributed to the portal users exceeded 2x the current production another round of testing after the R4.9 deployment once the portal environment is switched to production mode. Additionally, Microsoft is performing performance testing for DDD functionality and expects to deliver the results in January 2025. IV&V								
			re-assigning cases and opening the DDD - Contact Notes (Fiscal View - Complete) view.	completion 5/20/2024), identifying test cases and scenarios that include both DDD and CAMHD functionality, transactions/functionality that are performance intensive, e.g., calculator functionality 2. Conduct load and performance testing for each release that has significant new features/functionality, e.g., calculator-related transactions. 3. Create a plan for comprehensive performance testing and address any performance bottlenecks. 4. Have the benchmark assessments done annually and implementation of Azure App Insights for Power Platform.	annually to ensure system stability. 12/31/24 - Microsoft conducted performance testing for CAMHD functionality (MAX and Provider Portal) with 100, 200, and 300 users and delivered the performance report. According to the report, response times for MAX and NB/RIF emained consistent during each test. However, volumes at 300 portal users exceeded 2x the current production load, which Microsoft attributed to the portal running in trial index. Fils: caused degraded response times once user volume surpassed 200. Microsoft plans to conduct another round of testing after the R4.9 deployment once the portal environment is switched to production mode. Additionally, Microsoft is performing performance testing for DDD functionality and expects to deliver the results in January 2025. IV&V recommends that the project continues to prioritize completion of the testing and								
			re-assigning cases and opening the DDD - Contact Notes (Fiscal View - Complete) view.	completion 5/20/2024), identifying test cases and scenarios that include both DDD and CAMHD functionality, transactions/functionality that are performance intensive, e.g., calculator functionality 2. Conduct load and performance testing for each release that has significant new features/functionality, e.g., calculator-related transactions. 3. Create a plan for comprehensive performance testing and address any performance bottlenecks. 4. Have the benchmark assessments done annually and implementation of Azure App insights for Power Platform. 5. Execute test scripts that measure the run-time for execution of long-	annually to ensure system stability. 12/31/24 - Microsoft conducted performance testing for CAMHD functionality (MAX and Provider Portal) with 100, 200, and 300 users and delivered the performance report. According to the report, response times for MAX and INSPIE remained consistent during each test. However, volumes at 300 portal users exceeded 2x the current production load, which Microsoft attributed to the portal users exceeded 2x the current production another round of testing after the R4.9 deployment once the portal environment is switched to production mode. Additionally, Microsoft is performing performance testing for DDD functionality and expects to deliver the results in January 2025. IV&V								
			re-assigning cases and opening the DDD - Contact Notes (Fiscal View - Complete) view.	completion 5/20/2024), identifying test cases and scenarios that include both DDD and CAMHD functionality, transactions/functionality that are performance intensive, e.g., calculator functionality 2. Conduct load and performance testing for each release that has significant new features/functionality, e.g., calculator-related transactions. 3. Create a plan for comprehensive performance testing and address any performance bottlenecks. 4. Have the benchmark assessments done annually and implementation of Azure App Insights for Power Platform. 5. Execute test scripts that measure the run-time for execution of long- running transactions. E.g., calculator functionality/transactions and	annually to ensure system stability. 12/31/24 - Microsoft conducted performance testing for CAMHD functionality (MAX and Provider Portal) with 100, 200, and 300 users and delivered the performance report. According to the report, response times for MAX and INSPIRE remained consistent during each test. However, volumes at 300 portal users exceeded 2x the current production load, which Microsoft attributed to the portal running in trial inde. This caused degraded response times once user volume surpassed 200. Microsoft plans to conduct another round of testing after the HAS deployment conce the portal environment is switched to production mode. Additionally, Microsoft is performing performance testing for DDD functionality and expects to deliver the results in January 2025. IV&V providing the results.								
			re-assigning cases and opening the DDD - Contact Notes (Fiscal View - Complete) view.	completion 5/20/2024), identifying test cases and scenarios that include both DDD and CAMHD functionality, transactions/functionality that are performance intensive, e.g., calculator functionality 2. Conduct load and performance testing for each release that has significant new features/functionality, e.g., calculator-related transactions. 3. Create a plan for comprehensive performance testing and address any performance bottlenecks. 4. Have the benchmark assessments done annually and implementation of Azure App insights for Power Platform. 5. Execute test scripts that measure the run-time for execution of long-	annually to ensure system stability. 12/31/24 - Microsoft conducted performance testing for CAMHD functionality (MAX and Provider Portal) with 100, 200, and 300 users and delivered the performance report. According to the report, response times for MAX and INSPIRE remained consistent during each test. However, volumes at 300 portal users exceeded 2x the current production load, which Microsoft attributed to the portal running in trial mode. This caused degraded response times once user volume surpassed 200. Microsoft plans to conduct another round of testing after the R4.9 deployment once the portal environment is switched to production mode. Additionally, Microsoft is performing performance testing for DDD functionality and expects to deliver the results in January 2025. IV&V recommends that the project continues to prioritize completion of the testing and providing the results. 11/30/2024 -Due to BHA and Microsoft (MS) resourcing challenges, despite completing								
			re-assigning cases and opening the DDD - Contact Notes (Fiscal View - Complete) view.	completion 5/20/2024), identifying test cases and scenarios that include both DDD and CAMHD functionality, transactions/functionality that are performance intensive, e.g., calculator functionality 2. Conduct load and performance testing for each release that has significant new features/functionality, e.g., calculator-related transactions. 3. Create a plan for comprehensive performance testing and address any performance bottlenecks. 4. Have the benchmark assessments done annually and implementation of Azure App Insights for Power Platform. 5. Execute test scripts that measure the run-time for execution of long- running transactions. E.g., calculator functionality/transactions and	annually to ensure system stability. 12/31/24 - Microsoft conducted performance testing for CAMHD functionality (MAX and Provider Portal) with 100, 200, and 300 users and delivered the performance report. According to the report, response times for NAX and INSPIRE remained consistent during each test. However, volumes at 300 portal users exceeded 2x the current production load, which Microsoft attributed to the portal running in trial inder. This caused degraded response times once user volume surpassed 200. Microsoft plans to conduct another round of testing after the R4 9 deployment once the portal environment is switched to production mode. Additionally, Microsoft is performing performance testing for DDD functionality and expects to deliver the results in January 2025. IV&V recommends that the project continues to prioritize completion of the testing and providing the results. 11/30/224-Due to BHA and Microsoft (MS) resourcing challenges, despite completing the CAMHD performance test earlier, the project decided to execute the test from the								
			re-assigning cases and opening the DDD - Contact Notes (Fiscal View - Complete) view.	completion 5/20/2024), identifying test cases and scenarios that include both DDD and CAMHD functionality, transactions/functionality that are performance intensive, e.g., calculator functionality 2. Conduct load and performance testing for each release that has significant new features/functionality, e.g., calculator-related transactions. 3. Create a plan for comprehensive performance testing and address any performance bottlenecks. 4. Have the benchmark assessments done annually and implementation of Azure App Insights for Power Platform. 5. Execute test scripts that measure the run-time for execution of long- running transactions. E.g., calculator functionality/transactions and	annually to ensure system stability. 12/31/24 - Microsoft conducted performance testing for CAMHD functionality (MAX and Provider Portal) with 100, 200, and 300 users and delivered the performance report. According to the report, response times for MAX and NDSPIRE remained consistent during each test. However, volumes at 300 portal users exceeded 2x the current production load, which Microsoft attributed to the portal running in trail mode. This caused degraded response times once user volume surpassed 200. Microsoft plans to conduct another round of testing after the R4.9 deployment once the portal environment is switched to production mode. Additionally, Microsoft is performing performance testing for DDD functionality and expects to deliver the results in January 2025. IV&V recommends that the project continues to prioritize completion of the testing and providing the results. 11/30/2024 - Due to BHA and Microsoft (MS) resourcing challenges, despite completing the CAMHD performance test earlier, the project decided to execute the test from the beginning for DDD and CAMHD. NS has completed performance testing the CAMHD								
			re-assigning cases and opening the DDD - Contact Notes (Fiscal View - Complete) view.	completion 5/20/2024), identifying test cases and scenarios that include both DDD and CAMHD functionality, transactions/functionality that are performance intensive, e.g., calculator functionality 2. Conduct load and performance testing for each release that has significant new features/functionality, e.g., calculator-related transactions. 3. Create a plan for comprehensive performance testing and address any performance bottlenecks. 4. Have the benchmark assessments done annually and implementation of Azure App Insights for Power Platform. 5. Execute test scripts that measure the run-time for execution of long- running transactions. E.g., calculator functionality/transactions and	annually to ensure system stability. 12/31/24 - Microsoft conducted performance testing for CAMHD functionality (MAX and Provider Portal) with 100, 200, and 300 users and delivered the performance report. According to the report, response times for NAX and INSPite remained consistent during each test. However, volumes at 300 portal users exceeded 2x the current production load, which Microsoft attributed to the portal running in trial indet. This caused degraded response times once user volume surpassed 200. Microsoft plans to conduct another round of testing after the RA 9 deployment once the portal environment is switched to production mode. Additionally, Microsoft is performing performance testing for DDD functionality and expects to deliver the results in January 2025. IV&V recommends that the project continues to prioritize completion of the testing and providing the results. 11/30/2024-Due to BHA and Microsoft (MS) resourcing challenges, despite completing the CAMHD performance test earlier, the project dicided to execute the test from the beginning for both DDD and CAMHD. MS has completed performance testing the CAMHD functionality and will conduct performance testing the the DDD-scope terms and the ACMHD functionality and will conduct performance testing the CAMHD performance testing the CAMHD performance testing the CAMHD performance testing the results.								
			re-assigning cases and opening the DDD - Contact Notes (Fiscal View - Complete) view.	completion 5/20/2024), identifying test cases and scenarios that include both DDD and CAMHD functionality, transactions/functionality that are performance intensive, e.g., calculator functionality 2. Conduct load and performance testing for each release that has significant new features/functionality, e.g., calculator-related transactions. 3. Create a plan for comprehensive performance testing and address any performance bottlenecks. 4. Have the benchmark assessments done annually and implementation of Azure App Insights for Power Platform. 5. Execute test scripts that measure the run-time for execution of long- running transactions. E.g., calculator functionality/transactions and	annually to ensure system stability. 12/31/24 - Microsoft conducted performance testing for CAMHD functionality (MAX and Provider Portal) with 100, 200, and 300 users and delivered the performance report. According to the report, response times for MAX and NDSPIRE remained consistent during each test. However, volumes at 300 portal users exceeded 2x the current production load, which Microsoft attributed to the portal running in trail mode. This caused degraded response times once user volume surpassed 200. Microsoft plans to conduct another round of testing after the R4.9 deployment once the portal environment is switched to production mode. Additionally, Microsoft is performing performance testing for DDD functionality and expects to deliver the results in January 2025. IV&V recommends that the project continues to prioritize completion of the testing and providing the results. 11/30/2024 - Due to BHA and Microsoft (MS) resourcing challenges, despite completing the CAMHD performance test earlier, the project decided to execute the test from the beginning for DDD and CAMHD. NS has completed performance testing the CAMHD								
			re-assigning cases and opening the DDD - Contact Notes (Fiscal View - Complete) view.	completion 5/20/2024), identifying test cases and scenarios that include both DDD and CAMHD functionality, transactions/functionality that are performance intensive, e.g., calculator functionality 2. Conduct load and performance testing for each release that has significant new features/functionality, e.g., calculator-related transactions. 3. Create a plan for comprehensive performance testing and address any performance bottlenecks. 4. Have the benchmark assessments done annually and implementation of Azure App Insights for Power Platform. 5. Execute test scripts that measure the run-time for execution of long- running transactions. E.g., calculator functionality/transactions and	annually to ensure system stability. 13/31/24 - Microsoft conducted performance testing for CAMHD functionality (MAX and Provider Portal) with 100, 200, and 300 users and delivered the performance report. According to the report, response times for MAX and INSPIRE remained consistent during each test. However, volumes at 300 portal users exceeded 2x the current production load, which Microsoft attributed to the portal running in trial indet. This caused degraded response times once user volume surpassed 200. Microsoft pians to conduct another round of testing after the RA3 deployment once the portal environment is switched to production mode. Additionally, Microsoft is performing performance testing for DDD functionality and expects to deliver the results in January 2205. IV8V recommends that the project continues to prioritize completion of the testing and providing the results. 11/30/2024 -Due to BHA and Microsoft (MS) resourcing challenges, despite completing the CAMHD performance test earlier, the project dicided to execute the test from the beginning for both DDD and CAMHD. MS has completed performance testing the CAMHD functionality and ull conduct performance testing the the DDD-scoped terms after the deployment of R4.9 to production. The estimated timeline for completion is 1–2 weeks.								
			re-assigning cases and opening the DDD - Contact Notes (Fiscal View - Complete) view.	completion 5/20/2024), identifying test cases and scenarios that include both DDD and CAMHD functionality, transactions/functionality that are performance intensive, e.g., calculator functionality 2. Conduct load and performance testing for each release that has significant new features/functionality, e.g., calculator-related transactions. 3. Create a plan for comprehensive performance testing and address any performance bottlenecks. 4. Have the benchmark assessments done annually and implementation of Azure App Insights for Power Platform. 5. Execute test scripts that measure the run-time for execution of long- running transactions. E.g., calculator functionality/transactions and	annually to ensure system stability. 12/31/24 - Microsoft conducted performance testing for CAMHD functionality (MAX and Provider Portal) with 100, 200, and 300 users and delivered the performance report. According to the report, response times for NAX and INSPite remained consistent during each test. However, volumes at 300 portal users exceeded 2x the current production load, which Microsoft attributed to the portal running in trial indet. This caused degraded response times once user volume surpassed 200. Microsoft plans to conduct another round of testing after the RA 9 deployment once the portal environment is switched to production mode. Additionally, Microsoft is performing performance testing for DDD functionality and expects to deliver the results in January 2025. IV&V recommends that the project continues to prioritize completion of the testing and providing the results. 11/30/2024-Due to BHA and Microsoft (MS) resourcing challenges, despite completing the CAMHD performance test earlier, the project dicided to execute the test from the beginning for both DDD and CAMHD. MS has completed performance testing the CAMHD functionality and will conduct performance testing the the DDD-scope terms and the ACMHD functionality and will conduct performance testing the CAMHD performance testing the CAMHD performance testing the CAMHD performance testing the results.								
			re-assigning cases and opening the DDD - Contact Notes (Fiscal View - Complete) view.	completion 5/20/2024), identifying test cases and scenarios that include both DDD and CAMHD functionality, transactions/functionality that are performance intensive, e.g., calculator functionality 2. Conduct load and performance testing for each release that has significant new features/functionality, e.g., calculator-related transactions. 3. Create a plan for comprehensive performance testing and address any performance bottlenecks. 4. Have the benchmark assessments done annually and implementation of Azure App Insights for Power Platform. 5. Execute test scripts that measure the run-time for execution of long- running transactions. E.g., calculator functionality/transactions and	annually to ensure system stability. 13/31/24 - Microsoft conducted performance testing for CAMHD functionality (MAX and Provider Portal) with 100, 200, and 300 users and delivered the performance report. According to the report, response times for MAX and INSPIRE remained consistent during each test. However, volumes at 300 portal users exceeded 2x the current production load, which Microsoft attributed to the portal running in trial indet. This caused degraded response times once user volume surpassed 200. Microsoft pians to conduct another round of testing after the RA3 deployment once the portal environment is switched to production mode. Additionally, Microsoft is performing performance testing for DDD functionality and expects to deliver the results in January 2205. IV8V recommends that the project continues to prioritize completion of the testing and providing the results. 11/30/2024 -Due to BHA and Microsoft (MS) resourcing challenges, despite completing the CAMHD performance test earlier, the project dicided to execute the test from the beginning for both DDD and CAMHD. MS has completed performance testing the CAMHD functionality and ull conduct performance testing the the DDD-scoped terms after the deployment of R4.9 to production. The estimated timeline for completion is 1–2 weeks.								
			re-assigning cases and opening the DDD - Contact Notes (Fiscal View - Complete) view.	completion 5/20/2024), identifying test cases and scenarios that include both DDD and CAMHD functionality, transactions/functionality that are performance intensive, e.g., calculator functionality 2. Conduct load and performance testing for each release that has significant new features/functionality, e.g., calculator-related transactions. 3. Create a plan for comprehensive performance testing and address any performance bottlenecks. 4. Have the benchmark assessments done annually and implementation of Azure App Insights for Power Platform. 5. Execute test scripts that measure the run-time for execution of long- running transactions. E.g., calculator functionality/transactions and	annually to ensure system stability. 12/31/24 - Microsoft conducted performance testing for CAMHD functionality (MAX and Provider Portal) with 100, 200, and 300 users and delivered the performance report. According to the report, response times for MAX and NB/RIF emained consistent during each test. However, volumes at 300 portal users exceeded 2x the current production load, which Microsoft attributed to the portal running in trial inde. This caused degraded response times once user volume surpassed 200. Microsoft pians to conduct another round of testing after the HA 9 deployment conce the portal environment is switched to production mode. Additionally, Microsoft is performing performance testing for DDD functionality and expects to deliver the results in January 2025. IV&V recommends that the project continues to prioritize completion of the testing and providing the results. 11/30/2024 - Due to BHA and Microsoft (MS) resourcing challenges, despite completing the CAMHD performance test earlier, the project dacided to execute the test from the beginning for both DDD and CAMHD. MS has completed performance testing the CAMHD functionality and will conduct performance testing for the DDD-scoped items after the deployment of R4.9 to production. The estimated timeline for completion is 1-2 weeks. 10/31/24 - Microsoft is continuing performance testing of the application and will								
			re-assigning cases and opening the DDD - Contact Notes (Fiscal View - Complete) view.	completion 5/20/2024), identifying test cases and scenarios that include both DDD and CAMHD functionality, transactions/functionality that are performance intensive, e.g., calculator functionality 2. Conduct load and performance testing for each release that has significant new features/functionality, e.g., calculator-related transactions. 3. Create a plan for comprehensive performance testing and address any performance bottlenecks. 4. Have the benchmark assessments done annually and implementation of Azure App Insights for Power Platform. 5. Execute test scripts that measure the run-time for execution of long- running transactions. E.g., calculator functionality/transactions and	annually to ensure system stability. 12/31/24 - Microsoft conducted performance testing for CAMHD functionality (MAX and Provider Portal) with 100, 200, and 300 users and delivered the performance report. According to the report, response times for MAX and INSPIRE remained consistent during each test. However, volumes at 300 portal users exceeded 2x the current production load, which Microsoft attributed to the portal running in trial indet. This caused degraded response times once user volume surpassed 200. Microsoft plans to conduct another round of testing after the RA 9 deployment once the portal environment is switched to production mode. Additionally, Microsoft is performing performance testing for DDD functionality and expects to deliver the results in January 2025. IV&V recommends that the project continues to prioritize completion of the testing and providing the results. 11/30/2024. Due to BHA and Microsoft (MS) resourcing challenges, despite completing the CAMHD performance test earlier, the project decided to execute the test from the beginning for both DDD and CAMHD. MS has completed performance testing the CAMHD functionality and will conduct performance testing for the DDD-scoop Alems after the deployment of RA.9 to production. The estimated timeline for completion is 1-2 weeks. 10/31/24 - Microsoft is continuing performance testing of the application and will provide the results/report upon completion.After discussions with a project stakeholder.								

	hort lescription	Finding Statement	Analysis and Significance	Recommendation	Finding Update	Category	Туре	Priority S	tatus Closed D	ate Identi	ified Date Ov	wner	
14 Lin	imited BHA	Shortage of Behavioral Health Administration (BHA) project	Key BHA project resources have reported constraints on how much time they can devote to	1. IV&V recommends that BHA implement a structured knowledge transfer	2/28/25 - BHA is developing a succession plan to address the potential departure of key	Resource	Issue	Medium C	lpen	8/18/2	2023 Mi	ichael Fors	
res	esources	resources could lead to reduced productivity and project	the project. The departure of the Child and Adolescent Mental Health Division (CAMHD)	process when key personnel retire, including cross-training and documenting	personnel and is actively working on having resources document knowledge as team	Management							
		delays.	System Management Office Manager and CAMHD Inspire Project Lead could further impact	critical knowledge in the Dynamics Help Desk system. Regular updates to the	members transition. This proactive approach aims to ensure continuity and preserve								
			the project if DOH cannot acquire suitable resources. The lack of capacity of the DOH test		essential information. One example of this effort is creating a knowledge base within the								
			script developer has slowed DOH's automated test script development.	support smooth operational continuity.	Help Desk system in Dynamics, which serves as a centralized resource for								
			If BHA is unable to fully staff the project and their existing resources continue to be		troubleshooting and support processes. By documenting processes, workflows, and								
			constrained, the project could experience a reduction in productivity and project delays.	2. Utilizing peer-to-peer knowledge sharing, allowing experienced team	troubleshooting steps, BHA ensures that future staff can access the same information								
				members to informally share their expertise during team meetings.	and continue operations smoothly, even as experienced team members move on.								
				Additionally, creating internal documentation that outlines best practices and	1/31/25 - IV&V was informed that some cross-training had been conducted, but concerns								
				processes for developing security policies would serve as a self-service resource for the team.	remain regarding the insufficient knowledge transfer for critical tasks. While a limited								
				resource for the team.	amount of knowledge transfer occurred concerning the provider portal, it was highlighted								
				3. DDD and CAMHD have further discussions to optimize resource utilization									
				between the two divisions.	customer portals. This would help reduce the risks associated with knowledge gaps and								
				between the two divisions.	ensure continuity in operations, especially in the event of key personnel unavailability.								
				4. BHA should explore options for offloading project team members' daily	DDD plans to onboard a Tosca Automated Regression Testing Subject Matter Expert								
				responsibilities to other staff.	(SME) to address the resourcing issue and improve cross-training. The plans and timeline								
				responsibilities to other start.	for Tosca automated regression testing are being reviewed, with plans to commence								
				5. BHA should work quickly to create new positions and receive State	work on 3/1/2025.								
				approval.	101 N 01 37 47 2023.		1						
				approve.	12/31/24 - IV&V is concerned that limited resources at BHA could cause project delays		1						
				6. BHA should identify tasks and duties that they can ask the SI to assume, as	and affect system quality. For instance, IT staff and other departments have struggled to		1						
				permitted by the contract, which are presently being handled by BHA	find time to update and create security policies, as these tasks have not been prioritized								
				members.	alongside their regular duties. BHA submitted requests for new positions, which the State								
				members.	did not approve. The hope is that filling a key position will help address this issue,								
				7. BHA should explore the use of contractors to fulfill the functions for open	allowing the new hire to take on policy drafting or free up others to focus on these critical								
				project positions.	tasks. While there are resources for specific tasks, only a few people have the necessary								
				project positions.	skills. Expanding this knowledge and responsibility across the team is a key part of their								
					skins, Expanding this knowledge and responsibility across the team is a key part of their								
					pian.								
					11/30/24 - IV&V remains concerned that limited BHA resources could create project								
					delays and reduce system quality. BHA requested funding for additional project								
					resources, however the request was not approved by the State. BHA plans to resubmit								
9 Dr	eployment	Due to on-going deployment processes and technical	Several post-production bugs have been encountered in the Phase 4 release, R4.4.	1. The Project should consider automating deployments for resource savings,		Release/Deployment	Issue	Low C	Ipen		63	utam	
	rocess	execution issues, the Project may continue to encounter	Regarding the bug, "Human Services Research Institute (HSRI) flow is failing in production"	increased efficiency, consistency, faster time to market, improved	prompting the deployment of a hotfix with a workaround on 2/7/2025. Since the R4.10	Planning	13500		,pen			ilvadv	
pro-	1000033.	defects and challenges, e.g., when releases are in production	(bug# 34886	collaboration and reliability, scalability, version control integration, and	deployment, five additional unresolved production defects have been logged in Azure	r ianing					100	intudy	
		or in meeting projected timelines for production and non-	https://dev.azure.com/DOHBHA/DOH%20BHA%20INSPIRE/ workitems/edit/34886), what is	rollback capability.	DevOps (ADO): two high severity, two medium severity, and one low severity. Their Root								
		production deployments.	in development and deployed is vastly different from what was deployed to production.		Cause Analysis (RCA) is still pending. Additionally, the AER solution went live on								
				2. Ensure there are adequate and qualified resources to support the current	2/21/2025, and a Mid-Sprint Deployment (MSD) with two (2) new items were deployed								
			The root cause for these errors is currently being investigated.	deployment processes. This may require the support from RSM resources to	the same day. The R4.11 go-live is scheduled for 4/3/2025. IV&V will continue to monitor								
			ine root date for these of one of the territy being interribution	provide assistance and knowledge transfer for some of the more complex	the deployment quality of R4.10, FHIR, any MSDs, and the AER solution.								
			Repeatable documented release and deployment and resources experienced with	deployment components.	the deployment quality of N+10, Frint, any woos, and the Act solution.								
			deployments will help ensure that mistakes are minimized and that functionality is not	asproyment components	1/31/25 - R4.9 encountered deployment issues, prompting the creation of a defect in								
			mistakenly deprecated when deployments take place.	3. As appropriate, consult with RSM on best practices that BHA could employ			1						
						1	1	i		1			
				to support deployment.	workflows. The R4.10 go-live is scheduled for 2/6/2025. The FHIR development was completed and deployed to production on 1/29/25, with delays due to issues related to								
					completed and deployed to production on 1/29/25, with delays due to issues related to								
				4. Request the assistance of the RSM Solution Architect in reviewing and	completed and deployed to production on 1/29/25, with delays due to issues related to integrating with Microsoft and Apple Health. The AER solution go-live is scheduled for								
				 Request the assistance of the RSM Solution Architect in reviewing and correcting issues associated with the consistency of configurations across 	completed and deployed to production on 1/29/25, with delays due to issues related to integrating with Microsoft and Apple Health. The AER solution go-live is scheduled for 2/21/2025. IV&V will continue to monitor the deployment quality of R4.10, FHIR, any								
				 Request the assistance of the RSM Solution Architect in reviewing and correcting issues associated with the consistency of configurations across environments, ensuring that the test environment is capable of testing ALL 	completed and deployed to production on 1/29/25, with delays due to issues related to integrating with Microsoft and Apple Health. The AER solution go-live is scheduled for								
				 Request the assistance of the RSM Solution Architect in reviewing and correcting issues associated with the consistency of configurations across 	completed and deployed to production on 1/29/25, with delays due to issues related to integrating with Microsoft and Apple Health. The AE solution go-live is scheduled for 2/21/2025. IV&V will continue to monitor the deployment quality of R4.10, FHIR, any MSDs, and the AER solution.								
				4. Request the assistance of the RSM Solution Architect in reviewing and correcting issues associated with the consistency of configurations across environments, ensuring that the test environment is capable of testing ALL functions of any given release without the need for using multiple test	completed and deployed to production on 1/29/25, with delays due to issues related to integrating with Microsoft and Apple Health. The AER solution go-live is scheduled for 2/21/2025. IV&W will continue to enonitor the deployment quality of R4.10, FHIR, any MSDs, and the AER solution. 12/31/24 - The Root Cause Analysis (RCA) for the medium-severity defect (addressed								
				4. Request the assistance of the RSM Solution Architect in reviewing and correcting issues associated with the consistency of configurations across environments, ensuring that the test environment is capable of testing ALL functions of any given release without the need for using multiple test environments.	completed and deployed to production on 1/29/25, with delays due to issues related to integrating with Microsoft and Apple Health. The AEA Solution goilveis es scheduled for 2/21/2025. IV&V will continue to monitor the deployment quality of R4.10, FHIR, any MSDs, and the AER solution. 12/31/24 - The Root Cause Analysis (RCA) for the medium-severity defect (addressed with a hottix deployed on 10/24/2024) identified it as deployment-related (related to								
				Request the assistance of the RSM Solution Architect in reviewing and correcting issues associated with the consistency of configurations across environments, ensuring that the test environment is capable of testing ALL functions of any given release without the need for using multiple test environments. S. Request the assistance of the RSM Solution Architect in review of	completed and deployed to production on 1/29/25, with delays due to issues related to integrating with Microsoft and Apple Health. The AER solution go-live is scheduled for 2/21/2025. IV&V will continue to monitor the deployment quality of R4.10, FHR, any MSDs, and the AER solution. 12/31/24 - The Root Cause Analysis (RCA) for the medium-severity defect (addressed with a hoft's deployed on 10/24/2024) jdentified it as deployment-related (related to mising/removed workflows). R-9 was deployed to production on 12/2024, followed								
				4. Request the assistance of the RSM Solution Architect in reviewing and correcting issues associated with the consistency of configurations across environments, ensuing that the test environment is capable of testing ALL functions of any given release without the need for using multiple test environments. 5. Request the assistance of the RSM Solution Architect in review of deployment scripts as a double check for accuracy and completences prior to	completed and deployed to production on 1/29/25, with delays due to issues related to interparing with Microsoft and Apple Health. The AEA solution goilves is scheduled for 2/21/2025. IV&V will continue to monitor the deployment quality of R4.10, FHIR, any MSDs, and the AER solution. 12/31/24 - The Root Cause Analysis (RCA) for the medium-severity defect (addressed with a hotTx deployed on 10/24/2024) identified it as deployment-related (related to missing/removed workfow). R4.9 was deployed to production on 12/5/2024, followed by a mid-spirit deployment (MSD) with two uses stories on 12/16/2024. I&W will								
				Request the assistance of the RSM Solution Architect in reviewing and correcting issues associated with the consistency of configurations across environments, ensuring that the test environment is capable of testing ALL functions of any given release without the need for using multiple test environments. S. Request the assistance of the RSM Solution Architect in review of	completed and deployed to production on 1/29/25, with delays due to issues related to integrating with Microsoft and Apple Health. The AER solution go-live is scheduled for 2/21/2025. IV&V will continue to monitor the deployment quality of R4.10, FHR, any MSDs, and the AER solution. 12/31/24 - The Root Cause Analysis (RCA) for the medium-severity defect (addressed with a hoft's deployed on 10/24/2024) jdentified it as deployment-related (related to mising/removed workflows). R-9 was deployed to production on 12/2024, followed								
				Request the assistance of the RSM Solution Architect in reviewing and correcting issues associated with the consistency of configurations across environments, ensuring that the test environment is capable of testing ALL functions of any given release without the need for using multiple test environments. S. Request the assistance of the RSM Solution Architect in review of deployment scripts as a double check for accuracy and completeness prior to commencing deployment activities.	completed and deployed to production on 1/29/25, with delays due to issues related to intergrating with Microsoft and Apple Health. The AEA Solution golvies is scheduled for 2/21/2025. IV&V will continue to monitor the deployment quality of R4.10, FHIR, any MSDs, and the AER solution. 12/31/24 - The Root Cause Analysis (RCA) for the medium-severity defect (addressed with a hotfx deployed on 10/24/2024) identified it as deployment-related (related to missing/removed works). R4.9 was deployed to production on 12/5/2024, followed by a mid-spirit deployment (MSD) with two uses totics on 121/6/2024, lowed by a mid-spirit deployment (MSD) with two uses totics on 121/6/2024, lowed by a mid-spirit deployment (MSD) with two uses totics on 121/6/2024, lowed by a mid-spirit deployment (MSD) with two uses totics on 121/6/2024, lowed by a mid-spirit deployment (MSD) with two uses totics on 121/6/2024, lowed by a mid-spirit deployment (MSD).								
				Request the assistance of the RSM Solution Architect in reviewing and correcting issues associated with the consistency of configurations across environments, ensuring that the test environment is capable of testing ALL functions of any given release without the need for using multiple test environments. S. Request the assistance of the RSM Solution Architect in review of deployment scripts as a double check for accuracy and completeness prior to commencing deployment activities. 6. The Project Team should consider evaluating potential changes to	completed and deployed to production on 1/29/25, with delays due to issues related to integrating with Microsoft and Apple Health. The AEA solution go live is scheduled for 2/21/2025. IV&V will continue to monitor the deployment quality of R4.10, FHIR, any MSDs, and the AER solution. 12/31/24 - The Root Cause Analysis (RCA) for the medium-severity defect (addressed with a hortix deployed on 10/2/2024) identified it as deployment-related (related to missing/removed workflows). R4.9 was deployed to production on 12/5/2024, followed by a mid-spirint deployment (MSD) with two user stories on 12/16/2024. IV&V will monitor the quality of both the R4.9 deployment and the MSD. 11/30/2024 - The Root Cause Analysis (RCA) for the medium severity defect (for which a								
				Request the assistance of the RSM Solution Architect in reviewing and correcting issues associated with the consistency of configurations across environments, ensuring that the test environment is capable of testing ALL functions of any given release without the need for using multiple test environments. S. Request the assistance of the RSM Solution Architect in review of deployment scripts as a double check for accuracy and completeness prior to commencing deployment activities. G. The Project Team should consider evaluating potential changes to improve/enhance existing processes and communications to address current	completed and deployed to production on 1/29/25, with delays due to issues related to integrating with Microsoft and Apple Health. The AER solution go live is scheduled for 2/21/2025. IV&V will continue to monitor the deployment quality of R4.10, FHR, any MSDs, and the AER solution. 12/31/24 - The Root Cause Analysis (RCA) for the medium-severity defect (addressed with a hotfix deployed on 10/24/2024) identified it as deployment-related (related to missing/removed workflows). R4.9 was deployed to production on 12/5/2024, followed by a missingrit deployment (MSD) with two user stories on 12/5/2024, IV&V will monitor the quality of both the R4.9 deployment and the MSD. 11/30/2024 - The Root Cause Analysis (RCA) for the medium severity defect (for which a hot fix was deployed on 10/24/21/4) is still pending. There were no deployments in								
				Request the assistance of the RSM Solution Architect in reviewing and correcting issues associated with the consistency of configurations across environments, ensuring that the test environment is capable of testing ALL functions of any given release without the need for using multiple test environments. S. Request the assistance of the RSM Solution Architect in review of deployment scripts as a double check for accuracy and completeness prior to commencing deployment activities. 6. The Project Team should consider evaluating potential changes to	completed and deployed to production on 1/29/25, with delays due to issues related to intergraing with Microsoft and Apple Health. The AEA Solution golvies is scheduled for 2/21/2025. IV&V will continue to monitor the deployment quality of R4.10, FHIR, any MSDs, and the AER solution. 12/31/24 - The Root Cause Analysis (RCA) for the medium-severity defect (addressed with a hotfx deployed on 10/24/2024) identified it as deployment-related (related to missing/removed workflows). R4.9 was deployed to production on 12/5/2024, followed by a mid-sprint deployment (MSD) with two user stories on 12/16/2024. IV&V will monitor the quality of both the R4.9 deployment and the MSD. 11/30/2024 - The Root Cause Analysis (RCA) for the medium severity defect (for which a hot fix was deployed on 10/24/201 is still pending. There were no deployment in November 2024. R4.9 is scheduled to be deployed to December 2024. IV&V will will monitor in R4.80 will be and the R4.9 will be related to be deployed to the R4.80 will will R4.80 will monitor in R4.80 will be and the R4.90 will be related to be deployed to R4.80 will be related in the R4.80 will be related to be deployed by R4.80 will be related to be deployed to R4.80 will be related to be deployed by R4.80 will be related R5.00 will								
				Request the assistance of the RSM Solution Architect in reviewing and correcting issues associated with the consistency of configurations across environments, ensuring that the test environment is capable of testing ALL functions of any given release without the need for using multiple test environments. S. Request the assistance of the RSM Solution Architect in review of deployment scripts as a double check for accuracy and completeness prior to commencing deployment activities. S. The Project Team should consider evaluating potential changes to improve/enhance existing processes and communications to address current release/deployment scrifts.	completed and deployed to production on 1/29/25, with delays due to issues related to integrating with Microsoft and Apple Health. The AER solution go live is scheduled for 2/21/2025. IV&V will continue to monitor the deployment quality of R4.10, FHR, any MSDs, and the AER solution. 12/31/24 - The Root Cause Analysis (RCA) for the medium-severity defect (addressed with a hotfix deployed on 10/24/2024) identified it as deployment-related (related to missing/removed workflows). R4.9 was deployed to production on 12/5/2024, followed by a missingrit deployment (MSD) with two user stories on 12/5/2024, IV&V will monitor the quality of both the R4.9 deployment and the MSD. 11/30/2024 - The Root Cause Analysis (RCA) for the medium severity defect (for which a hot fix was deployed on 10/24/21/4) is still pending. There were no deployments in								
				Request the assistance of the RSM Solution Architect in reviewing and correcting issues associated with the consistency of configurations across environments, ensuring that the test environment is capable of testing ALL functions of any given release without the need for using multiple test environments. S. Request the assistance of the RSM Solution Architect in review of deployment scripts as a double check for accuracy and completeness prior to commencing deployment activities. S. The Project Team should consider evaluating potential changes to improve/enhance existing processes and communications to address current release/deployment scripts. J. IV&V recommends performing an RCA in collaboration with RSM for the	completed and deployed to production on 1/29/25, with delays due to issues related to integrating with Microsoft and Apple Health. The AEA Solution golvies is scheduled for 2/21/2025. IV&V will continue to monitor the deployment quality of R4.10, FHIR, any MSDs, and the AER solution. 12/31/24 - The Root Cause Analysis (RCA) for the medium-severity defect (addressed with a hotTx deployed on 10/24/2024) identified it as deployment-related (related to missing/removed workflows). R4.9 was deployed to production on 12/5/2024, followed by a mid-sprint deployment (MSO) with two user stories on 12/16/2024. IV&V will monitor the quality of both the R4.9 deployment and the MSD. 11/30/2024 - The Root Cause Analysis (RCA) for the medium severity defect (for which a hot fix was deployed on 10/24/24) is still pending. There were no deployments in November 2024; R4.9 is scheduled to be deployed.								
				Request the assistance of the RSM Solution Architect in reviewing and correcting issues associated with the consistency of configurations across environments, ensuring that the test environment is capable of testing ALL functions of any given release without the need for using multiple test environments. S. Request the assistance of the RSM Solution Architect in review of deployment scripts as a double check for accuracy and completeness prior to commencing deployment activities. S. The Project Team should consider evaluating potential changes to improve/enhance existing processes and communications to address current release/deployment scrifts.	completed and deployed to production on 1/29/25, with delays due to issues related to integrating with Microsoft and Apple Health. The AER solution go-live is scheduled for 2/1/2025. IV&V will continue to monitor the deployment quality of R4.10, FHIR, any MSDs, and the AER solution. 12/31/24 - The Root Cause Analysis (RCA) for the medium-severity defect (addressed with a hortix deployed on 10/24/2024) identified it as deployment-related (related to missing/removed workflows). R4.9 was deployed to production on 12/5/2024, followed by a mid-sprint deployment (MSD) with two user stories on 12/16/2024. IV&V will monitor the quality of both the R4.9 deployment and the MSD. 11/30/2024 - The Root Cause Analysis (RCA) for the medium severity defect (for which a hort fix was deployed on 10/24/24) is still pending. There were no deployments in November 2024. R4.9 is scheduled to be deployed in December 2024. IV&V will monitor the quality of the upcoming R4.9 deployment and MSDs. 10/31/24 - R4.8 was deployed to production on 10/16/24, instead of 10/3/24. This delay								
				Request the assistance of the RSM Solution Architect in reviewing and correcting issues associated with the consistency of configurations across environments, ensuring that the test environment is capable of testing ALL functions of any given release without the need for using multiple test environments. S. Request the assistance of the RSM Solution Architect in review of deployment acripts as a double check for accuracy and completeness prior to commencing deployment activities. S. The Project Team should consider evaluating potential changes to improve/nhance existing processes and communications to address current release/deployment sortfalls. 7. IV&V recommends performing an RCA in collaboration with RSM for the continued concerns surrounding environment differences.	completed and deployed to production on 1/29/25, with delays due to issues related to integrating with Microsoft and Apple Health. The AER Solution golvies is scheduled for 2/12/12025. IV&W will continue to monitor the deployment quality of R4.10, FHIR, any MSDs, and the AER solution. 12/31/24 - The Root Cause Analysis (RCA) for the medium-severity defect (addressed with a hottk deployed on 10/24/2024) identified it as deployment-related (related to missing/removed workflows). R4.9 was deployed to production on 12/5/2024, followed by a mid-spint deployment (MSO) with two user stories on 12/16/2024. IV&V will monitor the quality of both the R4.9 deployment and the MSD. 11/30/2024 - The Root Cause Analysis (RCA) for the medium-severity defect (for which a hot fix was deployed on 10/24/21/81 still panding. There were no deployments in November 2024, R4.9 is scheduled to be deployed in December 2024. IV&V will monitor the quality of the upcoming R4.9 deployment and MSDs. 10/31/24 - R4.8 was deployed to production on 10/16/24, instead of 10/3/24. This delay was caused by a Microsoft (MS) fix related to a periodus raised sehavioral Health								
				Request the assistance of the RSM Solution Architect in reviewing and correcting issues associated with the consistency of configurations across environments, ensuring that the test environment is capable of testing ALL functions of any given release without the need for using multiple test environments. S. Request the assistance of the RSM Solution Architect in review of deployment scripts as a double check for accuracy and completeness prior to commencing deployment activities. S. The Project Team should consider evaluating potential changes to improve/enhance existing processes and communications to address current release/deployment scripts. J. IV&V recommends performing an RCA in collaboration with RSM for the	completed and deployed to production on 1/29/25, with delays due to issues related to integrating with Microsoft and Apple Health. The AER solution go-live is scheduled for 2/1/2025. IV&V will continue to monitor the deployment quality of R4.10, FHIR, any MSDs, and the AER solution. 12/31/24 - The Root Cause Analysis (RCA) for the medium-severity defect (addressed with a hortix deployed on 10/24/2024) identified it as deployment-related (related to missing/removed workflows). R4.9 was deployed to production on 12/5/2024, followed by a mid-sprint deployment (MSD) with two user stories on 12/16/2024. IV&V will monitor the quality of both the R4.9 deployment and the MSD. 11/30/2024 - The Root Cause Analysis (RCA) for the medium severity defect (for which a hort fix was deployed on 10/24/24) is still pending. There were no deployments in November 2024. R4.9 is scheduled to be deployed in December 2024. IV&V will monitor the quality of the upcoming R4.9 deployment and MSDs. 10/31/24 - R4.8 was deployed to production on 10/16/24, instead of 10/3/24. This delay								

ID	Short	Finding Statement	Analysis and Significance	Recommendation	Finding Update	Category	Туре	Priority	Status Closed Date	Identified Date	Owner	
40	Insufficient	Insufficient testing processes can lead to poor-quality	There is a limited understanding of the testing processes and the roles and responsibilities of	IV&V recommends that, after fixing a defect, the SI incorporate relevant test	2/28/25 - R4.10 was deployed to production on 2/6/2025. Since the deployment of	Test Practice	Issue	Medium	Open	1/31/2024	Gautam	
	testing	software, project delays and extended user acceptance	those involved in the process. There is no formal process for the development, review, and	cases to validate these fixes in subsequent releases.	R4.10, five additional unresolved production defects have been recorded in Azure	Validation				-,,	Gulvady	
		testing.	approval of test scenarios, test cases, and test results to ensure adequate participation and		DevOps (ADO) (see Appendix E for details): two high severity, two medium severity, and							
			approval from state staff.	IV&V has requested discussions on various aspects of the INSPIRE testing	one low severity-despite testing at the unit, SIT, regression, joint, and smoke testing							
			When testing user stories 34564 and 34756 on 1/31/24, the test tasks did not reflect the real	process with a focus on process such as tracking test coverage and	levels. In response, the SI has committed to enhancing Smoke Test scripts to include							
			use cases to give stakeholders adequate confidence that the user story could be tested. As a	requirements traceability, considering new development of Access Rules,	more comprehensive testing, such as for the Provider Portal.							
			result, time was expended by testing resources, testing was inadequate, and a user story may	Document management/digitization.	The project plans to onboard an Automated Regression Testing Tool (Tosca) expert, with							
			have been deemed to meet functionality when it did not.		work planned to begin sometime in the month of March 2025. The project hopes to							
				A Stakeholder Register helps identify and understand all project stakeholders,	utilize this expert to repair their existing Tosca scripts so they can restart automated							
				ensuring their needs are met and risks are managed through effective	testing efforts.							
				communication. A RACI clarifies roles and responsibilities, improving	User Acceptance Testing for AER functionality was completed successfully with BHA							
				collaboration, decision-making, and resource management, which are all critical for the success of IT projects.	approving the AER testing deliverables. The AER solution went live on 2/21/2025.							
					1/31/25 - IV&V has been requesting a walkthrough of the INSPIRE testing process since							
				1. Identify stakeholders (output is stakeholder register) and develop a RACI	10/2024, which the SI has not delivered. IV&V will continue discussions with BHA to							
				matrix for testing.	ensure progress is made in advancing the SI's INSPIRE testing efforts. To support future		1					
					Phase 4 releases beyond R4.10, the project plans to onboard a Tosca automated		1					
				2. Review the overall testing process and implement any needed	regression testing Subject Matter Expert (SME). The plans and timeline for Tosca							
				improvements identified.	automated regression testing are being reviewed with plans to commence work on		1					
					3/1/2025. UAT for AER functionality is complete, with the SI addressing defects identified							
	1				during testing. Some AER testing deliverables, for example, test results, remain							
					incomplete, while BHA and IV&V are reviewing other deliverables.							
1	1				12/31/24 - IV&V provided a list of testing topics for the SI to address during the current							
	1				DD&I phase of the project. However, the SI's response focused on the M&O phase rather							
					than DD&I and did not reference updated documentation. BHA has communicated to the							
					SI that the project have always been in DD&I and the project can only transition to the							
					Maintenance and Operations (M&O) phase after CMS has certified INSPIRE/MAX. In							
					addition to updated documentation, IV&V continues to request a walkthrough meeting to							
					further understand the testing process. IV&V will continue discussions with BHA to							
					ensure progress is made in advancing the SI's testing efforts.							
					11/30/2024 - IV&V has identified specific testing areas to discuss with the appropriate							
41	Backlog	The absence of separate dedicated product backlog review	Currently, product backlog reviews are done during design meetings and/or weekly issues	Separate dedicated product backlog review meetings (during sprints) would		Sprint Planning	Risk	Medium	Open	1/26/2024	Gautam Gulvadv	
	meetings	meetings can lead to unclear priorities, misalignment with stakeholders, inadequate refinement, and increased risk of	meetings. This can lead to, e.g., scattered focus, limited stakeholder engagement, difficulty in managing complexity, and delayed decision making.	and refinement of backlog items. This would allow the project team to avoid	accordingly. While some meetings have already occurred, a consistent backlog review schedule is still being established. Efforts are also underway to improve the backlog						Guivady	
		scope creep.	A product backlog review is an essential part of agile project management, particularly in	situations where decisions about including items mid-sprint would have to be	review process. Regular meetings and process enhancements will help ensure alignment,							
		scope creep.	Scrum. It's a collaborative meeting where the Scrum team, including the Product Owner,	takon	facilitate timely issue resolution, and keep the project moving forward efficiently.							
			Scrum Master, and development team members, inspect and adapt the product backlog.	unch.	nuclinate timely issue resolution, and keep the project moving forward efficiently.							
			and and a second product of the prod	IVV recommends scheduling separate dedicated product backlog review	1/31/25 - BHA remains satisfied with the backlog prioritization. However, CAMHD,		1					
			The product backlog review is an important Scrum ceremony that helps keep the backlog	meetings (during sprints) where all relevant stakeholders are invited to review	having conducted surveys and user group interviews in 2019 and 2020, is concerned that							
			relevant, up-to-date, and aligned with the project's goals and priorities. Here's a summary of	the product backlog and scheduled at the appropriate time(s) such that there	gathering feedback from a broader user base might lead to additional requests without							
			what typically happens during a product backlog review:	is sufficient time to plan the design, development, and implementation (DDI)	proper prioritization. DDD mentioned that the next product backlog meeting is scheduled							
	1			of the next release(s).	for Monday, 2/2/2025, due to current team availability and ongoing commitments.							
	1		1. Inspecting Backlog Items: The team reviews the items on the product backlog. This involves		Additionally, IV&V will be invited to attend these backlog meetings.		1					
	1		discussing each item, understanding its priority, value, and acceptance criteria.				1					
	1		2. Ensuring Clarity: The team ensures that each backlog item is clear and well-understood. Any		12/31/24 -IV&V observed two CAMHD backlog prioritization meetings and will continue							
1	1		ambiguities or uncertainties are clarified at this stage.		to monitor the process regularly. While CAMHD and DDD are generally satisfied with the		1					
1	1		3. Estimation: Estimation of backlog items may occur during the review. The team may use		backlog prioritization, there are areas for improvement, particularly in balancing input							
	1		techniques like story points or relative sizing to estimate the effort required for each item.		from a broader user base and ensuring that federal compliance and performance-related		1					
1	1		4. Re-prioritization: Based on new insights, changes in requirements, or stakeholder feedback,		features are given appropriate attention in the backlog. By refining these aspects, both							
	1		the team may need to re-prioritize items in the backlog.		teams can improve the backlog prioritization process.							
	1		5. Removing or Adding Items: Items that are no longer relevant or necessary may be removed				1					
	1		from the backlog. New items that emerge or are identified as important may be added.		11/30/24 - The DDD team has scheduled a meeting for this month (November) to review							
	1		6. Refinement: Backlog refinement may also occur during the review. This involves breaking		the product backlog. During this session, the team will assess the current backlog items,							
	1		down large items into smaller, more manageable ones, or adding more detail to items as		prioritize them according to business value and urgency, and ensure they align with the							
	1		needed.		overall project goals. BHA plans to invite the IV&V team to participate in the backlog							
	1		7. Collaboration: The review is a collaborative effort involving the entire Scrum team. It's an		review meetings.		1					
1	1		opportunity for open discussion and sharing of ideas to ensure everyone is aligned on the goals				1					
1	1		and priorities.		10/31/24 - It has been confirmed that CAMHD holds bi-weekly product backlog review							
	1		8. Updating Documentation: Any updates or changes made during the review should be		meetings to review and adapt the product backlog. DDD communicated that they							
1	1		documented to ensure transparency and visibility for all stakeholders.		conduct collaborative reviews as needed and is yet to adopt regular dedicated product							
1	1		9. Feedback Loop: The review often generates feedback that can be used to improve the		backlog review meetings. IV&V recommends that DDD establish regular product backlog		1					
	1		backlog management process or refine future backlog items.		review sessions to ensure consistent alignment with project goals and prioritize tasks effectively.		1					
	1		10. Sprint Planning Preparation: The outcomes of the product backlog review help inform the upcoming sprint planning meeting, where the team selects items from the backlog to work on		chectively.		1					
	1		pupcoming spring planning meeting, where the team selects items from the backlog to work on		1							

	rt	Finding Statement	Analysis and Significance	Recommendation	Finding Update	Category	Туре	Priority	Status Clo	sed Date	Identified Date	Owner	
 Incone, 	ernance	Lack of effective governance and communication among	Ineffective governance and communication among stakeholders can significantly impact a	IVV recommends considering the following recommendations to establish	2/28/25 - DDD clarified that, except in cases of a missed requirement, any defect found	Project Management	Issue	Medium	Open		2/29/2024	Gautam	
		stakeholders can have significant negative impacts on a	project in several ways, e.g., stakeholder disengagement, misunderstandings, conflict and	effective governance and communication among stakeholders:	during testing incurs 0 USPs; otherwise, BHA is responsible for the cost of fixing the				·			Gulvady	
		project in several ways.	tension, misalignment of objectives, increased risks, unclear roles and responsibilities, and		defect.								
			quality issues. An example on this project is the development and implementation of Golden	1. BHA and the SI have discussions to align on a shared understanding of the									
			Record/Master Data Management (MDM).	contractual terms and conditions for the INSPIRE project.	1/31/25—The SI's response is that the project is in a staff augmentation phase, and BHA								
					now owns the project and decides where the SI puts its effort.								
			The lack of effective governance and communication among stakeholders can result in project										
			delays, budget overruns, and decreased quality. It's essential for project managers and stakeholders to prioritize clear communication and establish robust governance structures to		12/31/24 - Recent discussions between BHA and the SI during this reporting period indicate that BHA is utilizing additional User Story Points (USPs) to investigate and								
			ensure project success.	mechanisms. Clarify how decisions will be made, who has authority, and how issues will be resolved.	resolve defects from recent releases, such as R4.8. Based on earlier discussions with BHA,								
			ensure project success.	issues will be resolved.	IV&V understands that a warranty period applies to such defects, meaning the vendor								
				3. Develop a Stakeholder Registry, RACI chart, and Stakeholder Engagement	should not charge BHA additional costs for their resolution. However, the SI has stated								
					that there is no warranty period. IV&V and BHA will review the contractual terms and								
				the project lifecycle. Tailor communication strategies to address the needs	continue discussions in January 2025. The ultimate goal of this discussion is that all								
				and preferences of different stakeholders, ensuring their active involvement	stakeholders have a common understanding of the current contractual terms &								
				and support.	conditions governing defect fixing and how defect fixing will be addressed in the future.								
				 Clearly define Roles and Responsibilities: clearly outlining the roles and 	11/30/24 - IV&V is unaware of the progress towards mitigating this risk.								
				responsibilities of each stakeholder involved in the project, would ensure that everyone understands their duties and how they contribute to the project's	10/31/24 - The lack of productive communication between DDD and CAMHD could lead							1	
				success.	to misunderstandings, confusion, unclear project priorities, and ultimately project delays.								
					BHA is considering developing a documented governance process for restarting								
				5. Encourage Open Communication and Feedback: Foster a culture of open	production systems. The project is considering various options for tracking cost of								
				communication and feedback where stakeholders feel comfortable sharing	features that require a significant level of effort (project refers to these as "Big Rock"								
				their thoughts, concerns, and suggestions. Encourage constructive dialogue	features).								
				and actively seek input to improve decision-making and problem-solving. Keep									
				stakeholders informed about project progress, milestones, and key	9/30/24 - There remain some communication challenges between stakeholders on								
				developments through regular updates and progress reports. Highlight	project aspects such as defect tracking and reporting, and tracking and monitoring costs								
				achievements, challenges, and any changes to the project plan or scope.	related to Big Rock functionalities. IV&V recommends project teams maintain								
				6. Resolve Conflicts Promptly: Address conflicts and disagreements among	collaboration and information sharing across stakeholder groups to ensure shared								
				stakeholders promptly and professionally. Encourage dialogue, active	understanding in key project areas.								
					8/31/2024 - There remain some communication challenges between stakeholders on								
13 Share	rePoint	The process of updating DDD SharePoint folders took longer	The existing DDD SharePoint documents and folders update process is intensive and the	IV&V recommends doing an impact analysis, e.g., downstream impact.	2/28/25 - Further development on planned improvements to an existing process is linked	Release/Deployment	Issue	Low	Open		4/30/2024	Gautam	
folde	er	than anticipated.	execution time was unacceptable - this process took 11 calendar days to execute in production		to the scanning project. The SI has provided project cost and timeline information for the	Planning						Gulvady	
perfo	formance.		with R4.4.	IV&V recommends DDD puts on hold any development utilizing Power	restart of this project and is ready to commence the project. DDD has not yet received								
				Automate for the performance issue encountered in production (marked	the Governor's approval. Once approved, the scanning project will commence. IV&V has								
			This process is part of several intense processes that update SharePoint documents and	"TBD" in finding #14 related to "SharePoint Bulk Flows still running"), related	reduced the risk rating to low.								
			folders. The SI vendor recommended against doing this intensive process. However, no	user stores, e.g., "Changes to DDD folders", and defects.									
			feasible alternative solutions were provided and this process was implemented.	IV&V recommends evaluating other feasible options, e.g., leveraging	1/31/25 - DDD is working to confirm final approvals to allow the digitization initiative to move forward with the SI, and the project may restart in Spring 2025. Meanwhile, DDD								
			BHA has the flexibility to refine and alter their SharePoint directory structure. As a result, per	SharePoint tools and best practices.	has paused further development on planned improvements to an existing process, which								
			the SI vendor, the process does not pick up continuously evolving permutations of folder	sharer one cools and best practices.	previously took approximately 15 days to complete, as the current SharePoint site cannot								
			structures in Production, nor can the execution time be estimated or benchmarked. Per	A project issue should be opened to identify and manage the resolution of this	handle the anticipated volume of 2.5 million digitized documents without a redesign of								
			discussions between the SI vendor and BHA over many months, this process was not going to	issue.	its hierarchy.								
			complete 100% of the operations because of the different folder structures in Production. And										
			this process/jobs has been updated many times to address different folder structures that		12/31/24 - DDD is working with stakeholders to determine the direction and next steps								
			were captured during testing, but there is no guarantee that it covers every possible scenario -		on the digitization initiative.								
			some operations failed because the folder structure was not encountered during testing,									1	
			which was an expected event. The folders in Production that were not picked up with Flow		11/30/2024 – BHA plans to launch an initiative to digitize approximately 2.5 million								
			were supposed to be manually updated.		paper documents as part of a broader effort to transition to a paperless system. While the SI has been working on enhancing the existing process which previously required								
			The current solution utilizing Power Automate provided the necessary steps to automate this		around 15 days to complete, the current SharePoint site cannot accommodate the								
		1			anticipated volume without a redesign of the SharePoint hierarchy.							1	
			process, but it was never going to capture 100% of folders. And the process took 11 calendar			1	1	1			1	1	
			process, but it was never going to capture 100% of folders. And the process took 11 calendar days to execute in production.		Considering the low frequency of the process (only once or twice per year) and the		1						
					Considering the low frequency of the process (only once or twice per year) and the challenges posed by the SharePoint limitations, DDD has decided to pause further								
					challenges posed by the SharePoint limitations, DDD has decided to pause further								
					challenges posed by the SharePoint limitations, DDD has decided to pause further development on these improvements. However, if DDD encounters difficulties in executing the existing process, it will reevaluate the need for these enhancements.								
					challenges posed by the SharePoint limitations, DDD has decided to pause further development on these improvements. However, if DDD encounters difficulties in executing the existing process, it, will reevaluate the need for these enhancements. 10/31/24 - Development of the design improvements to create and rename folders for all								
					challenges posed by the SharePoint limitations, DDD has decided to pause further development on these improvements. However, if DDD encounters difficulties in executing the existing process, it will revaluate the need for these enhancements. 10/31/24 - Development of the design improvements to create and rename folders for all existing customers in their SharePoint subsite will begin as higher priority user stories								
					challenges posed by the SharePoint limitations, DDD has decided to pause further development on these improvements. However, if ODD encounters difficulties in executing the existing process, it will reevaluate the need for these enhancements. 10/31/24 - Development of the design improvements to create and rename folders for all existing customers in their SharePoint subsite will begin as higher priority user stories have been completed and a SharePoint resource becomes available. The new design will be								
					challenges posed by the SharePoint limitations, DDD has decided to pause further development on these improvements. However, if DDD encounters difficulties in executing the existing process, it will reevaluate the need for these enhancements. 10/31/24 - Development of the design improvements to create and rename folders for all existing customers in their SharePoint subsite will begin as higher priority user stories have been completed and a SharePoint resource becomes available. The new design will utilize PowerShell scripts, which are expected to be more efficient than the previously								
					challenges posed by the SharePoint limitations, DDD has decided to pause further development on these improvements. However, if ODD encounters difficulties in executing the existing process, it will reevaluate the need for these enhancements. 10/31/24 - Development of the design improvements to create and rename folders for all existing customers in their SharePoint subsite will begin as higher priority user stories have been completed and a SharePoint resource becomes available. The new design will be								

ID	Short	Finding Statement	Analysis and Significance	Recommendation	Finding Update	Category	Туре	Priority	Status Closed Date	Identified Date	Owner	
45	Description								Shared 2 (20) (2577	5/25/2024	6.1	
45	Cost tracking for big rocks	There is a lack of stakeholder alignment on cost tracking, federal financial participation allotments, and claims	The current process does not allow BHA to track actual costs versus budgeted costs of large functionality such as Provider Portal, Maui Wildfire Communication, Fast Health	IV&V recommends that stakeholders establish a structured process to ensure alignment and guide resolution.	2/28/25 - There has been no progress for this reporting period. Since BHA has no control over MQD's processes. IV&V is closing this risk for February 2025.	Project Management	Issue	Medium	Closed 2/28/2025	5/25/2024	Gautam Gulvady	
	I DIS TOCKS	management.	Interoperability Resources (FHIR) or the Golden Record (GR). The absence of a clear process	unginnent und Suide resolution.	over mego s processes. I view is closing this risk for repridity 2020.						Guivady	
1	1		doesn't give insight into, e.g., how much of the budget has gone into developing functionality		1/31/25 - Discussions between IV&V, BHA, and Med-QUEST continue to address		1	1		1		
1			such as Provider Portal, Maui Wildfire Communication, FHIR or GR functionality.		challenges in tracking federal financial participation allotments and managing claims		1	1				
					submissions. Efforts are underway to define a structured process to guide resolution.							
			By incorporating a clear process that would allow BHA to monitor costs of large functionality, BHA can maintain better financial records and it would allow BHA to track actual versus		12/31/24 -BHA has escalated Med-QUEST's ongoing challenges with tracking federal							
			budgeted costs and answer questions, e.g., "how much money has been spent on developing		financial participation allotments and managing its claims submission process to the							
			Provider Portal, Maui Wildfire Communication, FHIR or Golden Record (GR) functionality?"		appropriate personnel. The deployment of Fast Healthcare Interoperability Resources							
					(FHIR) has been postponed, with a new target date of January 2025. IV&V remains							
					concerned that scope creep in FHIR development could delay the implementation of							
					other system features, potentially impacting system performance, reducing user productivity, and increasing user frustration. PCG, BHA, and Med-QUEST are having							
					ongoing discussions to resolve Med-QUEST's challenges with tracking federal financial							
					participation allotments and managing its claims submission process.							
					11/30/2024 - During earlier discussions between BHA and IV&V, DDD emphasized the							
					importance of tracking costs for major functionalities like the Provider Portal and FHIR. In							
					September 2024, IV&V proposed options for cost tracking, including the use of Tags in Azure DevOps (ADO). BHA stakeholders suggested similar straightforward methods,							
					aligning with IV&V's recommendation. Since BHA is currently satisfied with the system							
	1				integrator's (SI) adherence to the allocated budget for key functionalities, BHA does not					1		
	1				consider this as a risk. However, BHA has raised significant concerns about Med-QUEST's					1		
1	1				ongoing inability to track federal financial participation allotments and its claims		1	1		1		
	1				submission process, issues that have persisted since the project's inception. These					1		
	1				deficiencies require considerable time to make corrections and may require additional					1		
1	1				funding. Despite previous assurances of procedural improvements, the problem remains unresolved.		1	1		1		
1							1	1				
	1				10/31/24 - Discussions about the options are ongoing. These options also enable tracking					1		
	1				the allocation of a release's fixed number of User Story Points (USPs) across various					1		
—					categories or buckets by utilizing tags in Azure DevOps (ADO). IV&V is concerned that the		<u> </u>	1				
46	Defect	Neglecting the established defect management process could		IV&V recommends to:	2/28/25 - A high-priority defect occurred on 2/6/2025, bringing to light an opportunity to	Project Management	Issue	Medium	Open	9/30/2024	Gautam	
	management.	lead to lost/forgotten defects, user frustration, and could slow resolution of similar defects in the future.		1. The project records the history of a defect's severity in the corresponding ticket's description/notes section in ADO. For example, when a hotfix is	strengthen the project's defect management process. BHA encountered some challenges that resulted in a delay in addressing the defect. In February, there were productive					1	Gulvady	
	1	resolution of similar defects in the ruture.		deployed to mitigate a defect initially classified as "Critical," the	discussions on addressing critical defects. The SI has provided a document outlining the					1		
	1			description/notes section should document that the defect originally had a	Help Desk process, which IV&V will review in March 2025 to further determine the risk.					1		
	1			"Critical" severity rating.						1		
1	1			2. Based on Best Practice wipdating the defect management documentation	1/31/25 - During this reporting period, there continues to be a delay in creating tickets in		1	1		1		
	1			and having regular refresher training on the defect management process.	Azure DevOps (ADO) for defects. IV&V remains concerned about the project's deviation					1		
	1			 Send communications to the project stakeholders to clarify the defect management process and the importance of logging all defects. 	from the Defect Management process. IV&V, BHA and the SI will continue discussions to identify process gaps and determine next steps.					1		
	1			3. Take steps to assure current and new users understand how to report	nuentity process gaps and determine next steps.					1		
	1			and/or log defects.	12/31/24 - During this reporting period, users encountered production issues related to					1		
1	1			4. Consider designating a defect management lead or champion to oversee	the Calculator, including an inability to view active cases and resolved cases. However,		1	1		1		
	1			adherence to the process and assure all defects are logged.	the corresponding tickets were not promptly created in Azure DevOps (ADO). IV&V					1		
	1			5. Keep stakeholders informed about defect status, priority, impacts, and	remains concerned about the project's non-adherence to the Defect Management					1		
	1			resolution timelines. This could increase awareness of the importance of	process. IV&V and BHA will continue discussions to identify process gaps and determine next steps.					1		
1	1			logging defects. 6. Discuss ways to improve the defect logging and management process with	Text steps.		1	1		1		
	1			the SI and come up with a plan to improve.	11/30/2024 - In recent meetings with DDD and CAMHD, IV&V discussed the issue of					1		
1					some defects reported to the Helpdesk via phone or other channels not being logged or		1	1				
	1				addressed. DDD noted that staff find the process of logging such defects cumbersome.					1		
	1				However, DDD leadership has emphasized that all defects must be logged. IV&V and BHA					1		
1	1				to continue these discussions to determine process gaps and the next steps.		1	1		1		
	1				10/31/24 - DOH leadership continues to express concerns that not all defects are being					1		
	1				logged.					1		
	1									1		
1							1	1				
1							1	1				
1							1	1				
47	Production	The lack of a governance process for restarting production		IV&V recommends BHA	2/28/25 - There has been no progress for this reporting period.	Project Management	Issue	Medium	Open	9/30/2024	Gautam	
1	restarts.	systems can impact service availability and frustrate end-		1. Develop standard procedures for system restarts, including a checklist to			1	1			Gulvady	
	1	users and hinder accountability.		determine when a restart is necessary, pre-checks, step-by-step instructions,	1/31/25 - When an issue requiring a production Portal restart occurred only once, certain					1		
1	1			and post-restart verifications.	project stakeholders convened to discuss and implement the necessary steps. IV&V		1	1		1		
1	1			2. Require formal approvals before initiating a restart, especially for INSPIRE,	recommends documenting the actions taken during that meeting as part of the process		1	1		1		
1	1			and document all actions in a centralized system. 3. Define clear escalation paths for when restarts do not go as planned,	for production system restarts. Documenting processes and procedures removes ambiguity and ensures a common understanding among stakeholders.		1	1		1		
	1			including identifying contacts for technical support and management approva	anosbarry and cristics a common understanding among stakeholders.					1		
	1			for additional interventions.	12/31/24 - BHA suggested that the deployment team or the Help Desk team may be best					1		
	1			4. Automate Restart Procedures where possible.	suited to document the process. IV&V remains concerned that no further progress has					1		
1				5. The governance process is established, it should be effectively	been made and will continue to make recommendations on how BHA could resolve this		1	1				
	1			communicated to the project team.	issue and be prepared for a production restart.					1		
1				Provide stakeholders with a clear explanation of the reason for the restart and the loccorr logrand while documenting the restart details in the defect	11/20/24 No program has been made for this security		1	1				
	1			and the lessons learned, while documenting the restart details in the defect	11/30/24 - No progress has been made for this reporting period.					1		
1					10/31/24 - BHA is considering developing a documented governance process for		1	1				
1					restarting production systems.		1	1				
	1									1		
	1	1	1		1		1	1	L	-	1	l

ID	Short	Finding Statement	Analysis and Significance	Recommendation	Finding Update	Category	Туре	Priority	Status	Closed Date	Identified Date	Owner
	Description											
49	Unreported	Multiple AERs for a single episode and unresolved false	SI has yet to demonstrate that multiple AERs are not created for a single episode and that an	IV&V recommends that the SI vendor validate the logic to address BHA's	2/28/25 - DDD informed IV&V that the SI's AER team has successfully designed and	Project Management	Issue	Medium	Closed	2/28/2025	12/17/2024	Gautam
	AERs and false	positives could hinder CaseManager's ability to resolve	AER record should match an unreported AER record. These concerns arise from the use of	concerns.	demonstrated functional, visually appealing dashboards. Phase 1 of the AER solution,							Gulvady
	positives.	unreported AERs.	claims data to identify unreported AERs and to address false positives - events initially flagged		focused on Case Management, has completed UAT and went live on 2/21/2025. A Mid-							
			as adverse but later determined not to be. If left unresolved, these issues could hinder the		Sprint Deployment (MSD) on the same day introduced two new items: unreported AERs			1				
			Case Managers' ability to effectively resolve unreported false positives.		and false positives.			1				
					Additionally, new requests-such as enhanced reporting for the Outcomes & Compliance			1				
			As Case Managers create AERs for unreported AERs, the number of unreported AERs should		Branch (OCB), Clinical Integration Team (CIT), and Community Resources Branch (CRB) on			1				
			decrease. Currently, the solution tracks reported and unreported AERs but currently there is		trending insights—are being designed and will be deployed in Phase 2. IV&V has closed			1				
			no way to simultaneously reduce unreported AERs and increase reported AERs.		this finding because DDD confirmed that currently the claims are getting attributed to an			1				
					unreported AER, and DDD is satisfied with how it works.			1				
					1/31/25 - : The vendor has built the AER solution in accordance with project			1				
					requirements and is actively working toward its completion. DDD has informed IV&V that							
50	Training	There is uncertainty around the scheduling, trainee groupings,	BHA has requested the SI for a complete updated AER project schedule which is yet to be		2/28/25 - IV&V was informed that the RSM team members had demonstrated strong	Schedule Managemen	t Preliminary		Closed	2/28/2025	1/31/2025	Susmitha
	Materials	and access to training materials for the upcoming sessions.	delivered. It is essential for the project team to review training materials in advance to ensure		troubleshooting skills. During the UAT phase, they were able to quickly diagnose issues,		Concern	1				Rajan
			they are properly aligned with the distinct needs of each trainee group. Given the differences		showcasing their efficiency in problem-solving.			1				
			in the users' dashboards, users will not be trained together, necessitating the reservation of									
			specific times for each group. Furthermore, the SI vendor is prepared to engage in discussions		In the third supervisor training session, one of the trainees had trouble viewing the			1				
			and provide a preview of the materials that have already been developed. This preview will be		screen. The RSM team member addressed the issue by providing the trainee with the			1				
			valuable for refining content, ensuring it is relevant, and confirming that the materials meet		relevant page numbers from the training manual, ensuring they could follow along			1				
	1		the requirements of each user group.		without any disruption.							
	1											
1	1				As the issue was resolved, we are now closing this preliminary concern.							
i i												